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ABSTRACT 
Introduction, Methods, Results and Discussion/Conclusion 
The existence of Cancer Stem Cells (CSC’s) has been proven extensively in recent years. 
CSC’s have been positively identified in, and isolated from colon cancer. They have been 
found to be resilient to therapy and are highly metastatic and it has been suggested that this 
could be attributed to the presence of CSC’s expressing cell surface CD133. An active 
Hedgehog-Gli pathway has been detected in human colon carcinoma cells as well as their 
stem cells. Sonic Hedgehog (Shh) inhibitors such as cyclopamine have been successful in the 
treatment of other cancer types.  
 
CSC’s were isolated from HT29 and DLD1 cells using the CD133 surface protein and these 
cells were further characterized via their expression of key stem cell markers using 
fluorescence microscopy. These markers included c-Myc, KLF4 and alkaline phosphatase, all 
of which showed elevated expression levels in the CSC fraction. The growth pattern of 
CSC’s in comparison to non-CSC’s was analyzed using cell-impedance (xCELLigence) 
assays, with clear differences noted in their growth rates. Adhesion assays revealed that 
although CSC’s have a lower proliferation rate, their adhesive potential proved to be greater, 
possibly due to them being highly metastatic. The effects of the Shh inhibitors cyclopamine 
and SANT-2 on cellular adhesion of colon CSC’s were compared to the Shh pathway control 
molecule tomatidine, and a marked decrease in adhesion potential was noted. With regard to 
cell invasion, this was significantly decreased when CSC’s were treated with the small 
molecule inhibitors. In cell migration/scratch assays a similar trend was seen, wherein cell 
migration was retarded by Hh pathway inhibition. Using confocal microscopy, the cell 
surface expression of Shh and CD133 was observed following treatment with cyclopamine 
and while found to significantly reduce Shh expression, CD133 expression remained 
unaffected.  
 
Considering these in vitro results small molecule inhibitors targeting the Shh pathway appear 
to be promising therapeutic tools for the treatment of metastatic colon CSC’s. Further 
investigation into the genes involved using PCR arrays would provide more detailed 
information on the drug action and allow for the development of an enhanced therapeutic.  
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1. INTRODUCTION 
1.1 COLON CANCER 
Colorectal cancer, commonly known as colon cancer or bowel cancer is a cancer from 
uncontrolled cell growth in the colon or rectum that forms part of the large intestine and 
usually develops from dysplastic adenomatous polyps1. This type of cancer was ranked as the 
fifth most common among males and third most common among females2 with 41 000 new  
cases reported in 20123. With a lifetime risk of 1 in every 98 males in South Africa the 
urgency for therapeutics is clear. Risk factors include increasing age4-6, males7, excessive 
intake of alcohol and red meat, obesity, smoking and a sedentary lifestyle8. Adenocarcinomas 
make up more than 95% of all cases with the remaining 5% being neuroendocrine tumours 
and small cell carcinomas9.  
 
Single-base pair mutations within the ras-gene10,11 or allelic deletion of chromosome 512 are 
the two prominent genetic alterations that occur in colorectal neoplasia. These in combination 
with losses in the chromosome 17 and 18 ras sequences have been found to result in the 
formation of colorectal adenomas13,14. The Vogelstein model suggests that for colorectal 
tumorigenesis to progress there must be mutational activation of an oncogene in conjunction   
with the loss of tumour suppressor genes15. The three dominant conditions that are thought to 
influence the development of colorectal cancer include polyps, familial polyposis and 
ulcerative colitis. The polyp-cancer sequence suggests that the majority of colorectal 
neoplasia form as a result of adenomatous polyps and villous adenomas16. 
 
The key factors that distinguish malignant tumours from benign tumours include the ability to 
infiltrate surrounding tissue, the destructive nature of the cells as well as its highly metastatic 
potential. Colon cancer is classified according to the Dukes’ system which gives an indication 
of the degree of invasion and can be useful in treatment planning. Early detection is key as it 
then allows for successful surgery and curative treatment, however, unfortunately in most 
cases at diagnosis the advanced disease results in an estimated 5-year survival rate of merely 
8% 9. The prominent prognostic factor is the stage of the tumour with the degree of bowel 
wall invasion, lymph node metastasis and distant metastases negatively affecting the 
prognosis of the patient17.   
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Table 1: Dukes’ classification for colon cancer staging  
Stage Criterion 
A Tumour confined to the intestinal wall 
B Tumour invading through the intestinal wall into muscle layer 
C Lymph node(s) involvement (this is further subdivided into C1 lymph node 
involvement where the apical node is not involved and C2 where the apical 
lymph node is involved) 
D Distant metastasis to other organs 
 
Currently, several modes of treatment are available such as surgery, chemotherapy, radiation 
therapy, immunotherapy and monoclonal antibody therapy. Other novel approaches include 
gene therapy18, non-pathogenic bacteria and telomerase therapy19. In cases where the tumour 
has become metastatic, treatment is challenging since various tissues are affected. In this 
study, colon cancer cell lines derived from tumours classified as Dukes’ stages B and C will 
be used for the in vitro testing of several therapeutic agents.  
1.2 CANCER STEM CELL THEORY 
In recent years an increasing amount of evidence supports the theory of human cancer being 
considered as a stem cell disease20-23. The theory suggests that the formation of solid tumours 
is not simply the result of monoclonal expansions of transformed cells but instead the tumour 
consists of tissue displaying abnormal growth caused by a group of Cancer Stem Cells 
(CSC’s) (Figure 1). This theory was proven in solid tumours when human breast cancer cells 
were grown in immuno-compromised mice; and it was noted that only a small population of 
breast cancer cells were capable of forming new tumours24. CSC’s have been positively 
identified in, and isolated from various human solid cancers including, breast24, brain25,26, 
colon27,28, head and neck29and pancreatic cancer30.    
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Figure 1: An illustration of the classical CSC concept. It is believed that tumours are heterogeneous 
and upon dissociation and transplantation into an immune-compromised mouse model, human CSC’s 
are able to reinitiate and form a similar heterogeneous tumour in vivo (own figure).  
 
 
Three important observations have been made proving the existence of CSC’s in solid 
tumours: 
1. Not all cancer cells possess the ability to form new tumours upon transplantation into 
immune-deficient mice, it is only a small population of the cancer cells that contain 
this tumorigenic potential.  
2. This special subpopulation of cancer cells can be identified by a distinctive profile of 
surface markers such as CD29, CD34, CD90, CD117 and CD13331. In this study 
CSC’s will be isolated from a population of cancer cells by magnetic cell separation 
using the CD133 marker. 
3. The secondary tumours formed from the CSC’s comprise of non-tumorigenic cancer 
cells as well as tumorigenic cancer cells that are further able to produce more 
tumours. In this way, the full phenotypic heterogeneity of the primary tumour is re-
created. 
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In adult tissue while normal adult stem cells assist in the maintenance of tissue that 
continuously regenerate, for example skin and gastrointestinal mucosa, regeneration also 
occurs in response to disease or injury32. Their capacity to self-renew is lifelong; they are 
multipotent and have the ability to switch between dormant and active states providing a level 
of resistance against cytotoxic drugs. CSC’s display similar characteristics and are able to 
self-renew and thereby form a new tumour from a small number of cells. In comparison with 
other cancer cells, CSC’s posses a lower proliferation rate and have also been found to be 
more resistant to chemotherapy and radiation treatments, due to the increased activity of 
membrane transporters31. The survival of even a few CSC’s following treatment poses a 
major health risk since these could result in a relapse of the tumour. This emphasizes the need 
to develop effective therapeutics targeting these cells. Currently several approaches for the 
eradication of these CSC’s are being explored33, including:  
• Targeting altered genetic signalling pathways by blocking specific cell surface 
molecules 
• Altering the cancer microenvironments that nurture CSC’s 
• Inducing differentiation of CSC’s 
• Immunotherapy based on CSC associated antigens 
• Exploiting metabolites to kill CSC’s 
• Designing small interfering RNA/DNA molecules that especially target CSC’s 
 
1.3 CD133 RECEPTOR 
Although there are a several markers that are helpful for the isolation of CSC’s from solid 
tumours, including CD133, CD44, EpCAM and ALDH activity, none of these markers are 
expressed exclusively by CSC’s 34. CD133 also known as Prominin-1 is a cell surface protein 
and will be used as a CSC marker in this study, being one of the prominent markers of CSC’s 
in colorectal cancer35. It is expressed in endothelial progenitor cells36, glioblastoma 
multiforme25, hematopoietic stem cells37, neuronal stem cells, glial stem cells38, as well as 
brain tumours 39. CD133 is also expressed in various other normal tissues including the 
trachea, salivary glands, digestive tract, kidney as well in reproductive organs such as the 
placenta, mammary glands and testes40,41. The expression and utility of CD133 has been well 
established in a number of colorectal cancer cell lines within the Oncology Laboratory. 
Furthermore, the expression of CD133 in patients with Dukes’ stages B and C cancer has 
been linked to the recurrence of tumours following therapy and a poor prognosis35. Presently 
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whilst the exact function of CD133 remains unknown, its expression during the production of 
the plasma membrane, and more specifically epithelial microvilli, indicates a possible role in 
this context. Recent literature has suggested that CD133 directly interacts with plasma 
membrane cholesterol and is predominantly found in plasma membrane protrusions42. Due to 
this association, it has been proposed that the functional role of CD133 is that of an 
“organizer” of the plasma membrane topology43-45. This interaction with cholesterol also 
infers that it may play a role in maintaining lipid composition within the plasma membrane. 
Cells expressing CD133 are thought to possess stemness properties which include their 
ability to self-renew, differentiate and form tumours in xenografts46. As further confirmation 
of the stem cell properties of cells expressing CD133, the expression of a number of 
additional markers will be assessed and these are described below. With regards to cell 
terminology, please note that CD133+ refers to cells that express cell surface CD133 (CSC’s: 
positive fraction from magnetic separation) and CD133- refers to cells that do no express 
surface CD133 (non- CSC’s: negative fraction from magnetic separation).  
1.4 OTHER STEM CELL MARKERS 
The use of CD133 as a definitive marker for CSC’s is debatable and some studies have 
shown that CD133 expression in colon cells is not necessarily restricted to stem cells, as it is 
also expressed on differentiated colonic epithelium47. It can therefore be suggested that 
CD133+ cells could very well contain stem cell like potential. Since CD133 may not 
exclusively be expressed by CSC’s, following the separation of cells using the CD133 
marker, they will then be further characterized using other markers.  
 
The Myc Oncogene 
 The regulator gene Myc codes for a transcription factor and in certain cancer types this gene 
has been found to be mutated causing its continuous expression. Myc is also activated upon 
several mitogenic signals, including Shh. Myc plays an active role in various processes such 
as cell proliferation, regulation of cell growth, apoptosis, differentiation and stem cell self-
renewal48, thereby making it an ideal CSC marker. Myc is also a key factor required for the 
induction of pluripotential stem cells that are required for stemness.  
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Krueppel-like factor 4 (KLF4)  
Another marker that will be considered is the KLF4 gene that encodes for Krueppel-like 
factor 4 (KLF4), a zinc-finger protein that contributes to the progression of gastric carcinoma 
by promoting tumour growth, invasion and metastasis49. It is thought to serve as a good 
indicator of stem-like capacity in embryonic stem cells and possibly even in mesenchymal 
stem cells. KLF4 was found to be one of the four genes essential for pluripotency in stem 
cells, others included Oct-3/4, SOX2 and as mentioned previously c-Myc50.   
 
Alkaline phosphatase 
The hydrolase enzyme alkaline phosphatase which is responsible for the removal of 
phosphate groups in nucleotides, proteins and alkaloids, will also be employed as a biomarker 
in this study. Alkaline phosphatase staining has been used in many instances to detect 
undifferentiated pluripotent stem cells as there are elevated levels contained on their cell 
membrane51. This method of staining is also implemented when the level of pluripotency is 
being evaluated and to positively identify embryonic stem cells52. Its utilization in detecting 
cancer stem cells is well established in various cancer cell lines including melanomas53 and 
ovarian cancer54.  
 
1.5 SONIC HEDGEHOG PATHWAY 
 
The Hh (Hedgehog) signalling pathway was named due to the appearance of the polypeptide 
ligand and intercellular signalling molecule Hh. Three Hh homologues have been identified 
in humans, Desert Hh, Indian Hh and the most widely studied Sonic Hedgehog (Shh)55. 
During embryonic development this pathway is a key regulator and ensures that symmetry as 
well as the correct distribution of cell types is maintained56. In knockout mice that lacked 
components of the pathway, it is of particular interest here that abnormalities were observed 
in the gastrointestinal tract, as well as brain, lungs, skeleton and musculature. In adult tissue 
the Hh pathway is mainly inactive57, but is thought to play a role in regulating adult stem 
cells which consequently maintain and regenerate old or damaged tissue. Moreover it is 
expressed in human adult gut epithelium58. 
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Reactivation of the Hh pathway in adult tissues may be linked to the development of some 
cancers (Figure 2). This may occur via genetic alterations in Hh pathway components or 
excessive secretion of Hh ligands. Certain cancers including basal cell carcinoma, 
medulloblastoma and rhabdomyosarcoma are attributed to mutations that either causes the 
activation of Smoothened (proto-oncogene) or the inactivation of Patched (tumour 
suppressor)59.  These two proteins play an imperative role in regulating the cellular response 
that occurs as a result of Hh. Oncogenic mutations in either Ptch (Patched) or Smo 
(Smoothened) could result in an increased activity of the Hh pathway60,61. As a result of the 
Smo suppression, the full length Gli1 translocates to the nucleus. This in turn causes the 
transcription of downstream genes including vascular endotheial growth factor (VEGF) and 
c-Myc62. Dependence of basal cell carcinomas and medulloblastomas on the Hh pathway has 
provided new targets for treating these cancers by targeting components of the pathway. In 
several cancer types including lung63,64, ovarian65, prostate66, breast67, endometrial68, skin69 
and gastrointestinal70-72, the pathway was found to be reactivated.  
 
Shh is believed to play an early and imperative role in the genesis of pancreatic cancer and is 
over-expressed in pancreatic adenocarcinoma as well as its precursor lesions73. It was also 
found that inhibition of this pathway by cyclopamine was able to induce apoptosis and hinder 
proliferation both in vitro and in vivo. With regards to colorectal cancer studies have 
indicated that Shh expression may prompt the adenoma-carcinoma sequence74; the Shh ligand 
as well as its downstream targets (Gli) are over-expressed in human colorectal cancer tissue75. 
An active Hh-Gli pathway was also positively identified in human colon carcinoma cells as 
well as its stem cells76. It is proposed in the present study that inhibiting the Shh pathway in 
colorectal CSC’s may be a novel approach leading to new treatments for colorectal cancer.  
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Figure 2: The mechanism by which the Shh pathway is reactivated: Ptch suppresses the activity of 
Smo, however, following the binding of the Hh ligand to Ptch, this suppression is then inhibited 
allowing for the activation of downstream targets through the Gli transcription factors. When a ligand 
is absent it results in the phosphorylation and cleavage of Gli; however, in the presence of a ligand, 
Gli is not cleaved and the full length Gli translocates to the nucleus where it exhibits transcriptional 
activity (own figure).  
1.6 SHH AND EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) 
A key process in metastatic cancer is the so-called Epithelial to Mesenchymal Transition 
(EMT), wherein epithelial cells loose the expression of E-cadherin and express N-cadherin, 
typical of motile mesenchymal cells77. Hh signalling activation results in EMT through FGF, 
Notch, TGF beta signalling cascades, and indirectly through miRNA regulatory networks77. 
A study by Higgins et al, suggested that Shh induces EMT in vitro and results in gene 
expression changes78. This was proven by inducing EMT in lung, breast and prostate cancer 
cells. Real-time PCR as well as immunofluorescence indicated that EMT had taken place and 
Matrigel™ assays confirmed the invasive potential of the phenotype present. Gene 
expression analysis using real-time PCR indicated the up-regulation of EMT genes, in 
particular an increase in the expression of N-cadherin, Gli2 and Shh genes. It was seen that 
the cells had undergone the switch to N-cadherin and these cells showed an increased ability 
to invade. In the same study it was demonstrated that the application of cyclopamine impeded 
this increased expression of N-cadherin, Shh as well as Gli2. In combination, these results 
imply that Shh is a crucial mediator of EMT in human tumours78.  
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1.7 SHH INHIBTION WITH CYCLOPAMINE 
 
The discovery of cyclopamine dates to the 1950’s with the occurrence of congenital 
abnormalities in newborn lambs in the highland areas of the Western United States. It was 
found that pregnant ewes that had grazed on the plant Corn Lily (Veratrum californicum) 
during day 14 of gestation would most likely result in newborn lambs with cyclopia, a single 
central eye. The compound responsible for these malformations was identified as an alkaloid, 
named cyclopamine (Figure 3).  
 
 
 
 
 
Figure 3: Chemical structure of cyclopamine with IUPAC name (3β,23R)-17,23-Epoxyveratraman-3-
ol and chemical formula C27H41NO2. 
 
Cyclopamine is thought to specifically inhibit the Hh response79,80, and may also play a role 
in the balance between active and  inactive forms of Smo, making it suitable for the treatment 
of cancers dependent on Smo activation (Figure 6). In a study using gastric primary cancer 
cells GAM-016 and MKN-45, it was found that cyclopamine successfully inhibited gastric 
cancer cell proliferation by inducing cell cycle arrest and apoptosis81. Cyclopamine acts as an 
antagonist of the Hh signalling pathway by directly binding to the Smo heptahelical domain82 
and in this way is able to induce apoptosis and block proliferation making it a potent cancer 
therapeutic. Other Shh inhibitors are discussed below.  
 
1.8 SHH INHIBITORS 
Current approaches for the treatment of cancer are limiting due to the cytotoxic effects that 
these therapeutics have on healthy proliferating tissue59. Ideally the most efficient drug would 
be one that is broad spectrum but non-toxic to healthy tissue. Therefore, alternatives such as 
‘mechanism-based’ therapies that are specific in targeting abnormally active signalling 
pathways could provide a solution with less collateral damage. In this case, targeting the Shh 
pathway is highly promising since its primary function is during the period of embryonic 
development and is not essential for survival in adults. The drugs evaluated in the present 
study include cyclopamine (see above), SANT2 and tomatidine. 
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SANT-2 
The cell-permeable SANT-2 molecule (Figure 4) being a potent antagonist of the Hh pathway 
is a useful tool for investigating Hh signalling. It acts by antagonizing the Smo receptor (KD= 
12nM) activity and inhibits SAG (Smo agonist) activity. Other Smo inhibitors such as 
GANT58 and JK184 were considered but proved to be unsuitable for this study as their effect 
is downstream of Smo and therefore, could not be used in comparison to cyclopamine. 
SANT-2 was selected from a range of cyclopamine analogues and will be used in this study 
and its effect or lack thereof, on cell invasion, adhesion and migration will be analyzed.  
 
 
 
 
Figure 4: Chemical structure of SANT-2 
Currently the only FDA approved drug targeting the Hh signalling pathway is Vismodegib 
(Erivedge). It has found to be effective in the treatment of basal-cell carcinoma and is 
undergoing clinical trials for implementation in the treatment of colorectal cancer, small-cell 
lung cancer, stomach cancer, pancreatic cancer and medulloblastoma55,83-86. In studies done to 
assess its efficacy as an advanced basal-cell carcinoma therapeutic, it was concluded to be a 
safe (FDA approved) and effective small molecule inhibitor of Smo87. Disease development 
in this case resulted from mutations in the Hh pathway leading to a loss in Ptch function. 
Cyclopamine as well as Vismodegib act on Smo directly, however other Shh inhibitors such 
as robotnikinin88 have an effect on the motor protein dynein (ciliobrevin A)89 or are able to 
hinder DNA-Gli interactions90(Figure 7).  
Tomatidine 
Many Shh studies make use of a steroidal alkaloid such as tomatidine (Figure 5) which is 
found in the skins of unripe tomatoes. They are structurally similar to cyclopamine but are 
non-teratogenic and have no effect on the Hh pathway91 making it useful as a negative 
control73.  
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Figure 5: Chemical structure of tomatidine  
 
Figure 6: The pathway inhibition induced by cyclopamine and SANT-2: both small molecules act as 
antagonists of Smo, preventing the activation of Gli and its movement into the nucleus, thereby 
preventing the transcription of oncogenes (own figure).  
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1.9 THE PRIMARY CILIUM 
It is important to discuss the primary cilium, since it has been found to be a central organelle 
in Hh signal transduction92. Moreover, it is the central location for many Hh pathway 
components including Shh, Ptch1, Smo and Gli transcription factors. Since the primary 
cilium acts as a sensory organelle, it is able to receive both mechanical as well as chemical 
signals and convey these to the nucleus, inducing a cellular response. As a result, any 
disruption in the localization of these proteins within the primary cilium would lead to an 
impedance of the signal. Overall, a functional and intact primary cilium is required for the 
modulation of the Shh pathway93.  
 
Cyclopamine and SANT-2 have differing effects on the primary cilium, in a study on 
NIH3T3 cells, cyclopamine treatment (10µM) caused localization of Smo to the primary 
cilium, while SANT-2 prevented the Shh-dependent translocation of the protein Smo to the 
primary cilium93. The same paper also discussed how SANT-2 was able to inhibit both a 
dominant active form of Smo (SmoA1) as well the wild-type Smo at comparable doses 
whereas cyclopamine was required at far higher doses to attain a similar inhibitory effect with 
SmoA159. On the contrary, in the present study, SANT-2 was required at comparatively 
higher concentrations than cyclopamine to induce an inhibitory effect on cell adhesion and 
invasion. 
 
In considering the aforementioned effects of SANT-2 and cyclopamine on Smo, together 
with their structural differences, it is thought that their binding to Smo occurs at differing 
sites. Furthermore, following their binding the conformational changes that are induced in 
Smo also differ, as well as the manner in which they hinder Smo interaction with other 
cellular factors93. It has also been shown that SANT-2 competes with cyclopamine for Smo 
binding, indicating that SANT-2 functions at the level of Smo which is upstream of SuFu94. 
The mechanism whereby cyclopamine inhibits the Shh pathway has been elucidated, being 
able to bind directly to the heptahelical bundle of Smo (Figure 7), possibly altering the Smo 
protein conformation82. This protein conformation is structurally similar to that of the surface 
protein Ptch. This understanding of the mode of action that cyclopamine has would allow for 
the progression in the therapeutic development of this small molecule since it may explain the 
trends noticed in this study. 
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Figure 7:  Inhibition strategies targeting the aberrant activation of the Shh pathway. Known activation 
events resulting in oncogenic development (purple boxes) juxtaposed with potential inhibition 
strategies (blue boxes). An appropriate inhibition strategy is key to successful treatment with small 
molecule inhibitors. The inhibitors utilized in this study specifically target Smo mutations (pink box) 
(Adapted from Figure 3, Drug Discovery Today, Therapeutic Strategies95). 
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1.10 EVALUATION OF NON-CSC’S VERSUS CSC’S 
 
It has been proposed that there are 6 distinct characteristics or hallmarks of cancer96 and these 
include:  
• Evasion of apoptosis 
• Insensitivity to anti-growth signals 
• Infinite replicative potential  
• Self-sufficiency in growth signalling  
• Induction and sustainment of angiogenesis 
• Ability to metastasize and invade surrounding tissue 
 
Similarly, cancer stem cells possess the following key properties97: 
• Ability to differentiate and give rise to all cell types  
• Ability to self-renew  
• Tumorigenic 
• Slow cycling and therefore resilient to conventional therapeutics 
• Resistance to therapy due to activation of several signalling pathways, such as Notch, 
Wnt/β-catenin, TGF-β, Hh, PI3K/Akt/mTOR and JAK/STAT pathways33 
• Highly metastatic33 
Several of these physiological traits can be evaluated in vitro using various assays 
including, invasion, adhesion, colony formation, proliferation and scratch assays. The 
efficacy of drugs on inhibiting these properties may be assessed using these same 
assays98. In this study several of these assays will be employed to either ascertain the 
differences between normal cancer cells and CSC’s or to evaluate the ability to inhibit the 
Shh pathway in CSC’s specifically.  
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2. HYPOTHESIS 
Considering the need for targeted therapy against CSC’s and their occurrence in colon 
cancers, as well as the role of Shh in EMT and metastasis, we therefore hypothesize that 
disrupting this pathway using small molecule inhibitors would be effective in impeding the 
invasive and adhesive potential of colorectal CSC’s.  
3. OBJECTIVES  
1. Isolation of a specific population of CSC’s from 3 colorectal cancer cell lines 
representing the middle and late stages of disease: 
a. By magnetic separation using the cell surface marker, CD133   
b. Confirmation of the CD133 stem cell isolation/population using flow cytometry 
 
Evaluation of the expression of the key stem cell markers, c-Myc, KLF4 and alkaline 
phosphatase in CSC’s and non-CSC’s using confocal microscopy.  
 
A real-time assessment of CSC proliferation relative to non-CSC’s with regards to: 
a. Time to confluency (proliferation rate) 
b. Number of cells required to reach confluency 
c. Growth pattern profiling  
 
2. Inhibition of the Shh pathway in colon CSC’s using the Smo inhibitors cyclopamine 
and SANT-2. The effects of these compounds was analyzed with regard to the 
following cellular parameters:    
  →cell adhesion         
             →cell invasion  
             →cell migration   
 
Evaluation of CD133 and Shh expression following Shh pathway inhibition, using 
fluorescence. 
 
(See flow diagram) 
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4. MATERIALS 
4.1 CELL CULTURE 
4.1.1 Cell lines  
Table 2: Cell lines used and their origin 
Cell line/Source Disease 
Neoplastic  
DLD1 (ATCC CCL-221™) Human colorectal adenocarcinoma Dukes’ type C 
(late) 
HT29 (ATCC HTB-38™) Human colorectal adenocarcinoma suspected Dukes’ 
type B  
SW480 (ATCC CCL-228™) Human colorectal adenocarcinoma Dukes’ type B 
(early) 
Note: For more detailed information on cell lines see Appendix A.  
An ethics waiver for the use of the abovementioned cell lines was obtained, see Appendix E. 
4.1.2 Cell culture media 
The mixed cell populations require different media prepared from the following components:  
• Dulbecco´s Modified Eagle’sMedium (DMEM) and Ham’s F-12(1:1 mix) (1x), (HT29 
and DLD1) (Biowhittaker® Lonza #BE12-719F).  
• RPMI 1640 (SW480) (Biowhittaker® Lonza) 
The above culture media was supplemented with: 
• 10% fetal calf serum (FCS) (heat inactivated) (HYCLONE® #SV30160.03).  
• 1% Penicillin/Streptomycin (Biowhittaker® Lonza #17-602E). 
The stem cell populations require media containing the following components (according to 
Mather, 2008): 
• 6mg/ml glucose 
• 1mg/ml NaHCO3  
• 2mM L-glutamine  
• 5mM HEPES 
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• 4µg/ml Heparin 
• 4mg/ml BSA (bovine serum albumin) 
• 10ng/ml βFGF (fibroblast growth factor) 
• 20ng/ml EGF (epidermal growth factor) 
• 100µg/ml apotransferrin 
• 25 µg/ml insulin 
• 9.6 µg/ml putrescine (diaminobutine) 
• 30nM sodium selenite anhydrous 
• 20nM progesterone 
 
The following stock solutions were prepared for the stem cell media:  
 Glucose 10% solution  
10g in 100ml sterile H2O 
 
 NaHCO3 7.5% solution 
7.5g in 100ml DMEM F12  
 
 Heparin 50mg/ml solution 
56mg in 1.12ml sterile H2O (mass may vary depending on batch) 
 
 EGF 1mg/ml solution 
2mg in 2ml acetic acid  
 
The stem cell media was prepared as follows:  
• DMEM F12 (1x), for (HT29 and DLD1) 
• RPMI 1640 (SW480) 
 
The above culture media was supplemented with (for 50ml media): *DMEM F12 contains 
HEPES, therefore none was added  
• 1% Penicillin/Streptomycin 
• 3ml Glucose (10% solution) (Merck) 
• 666 µl NaHCO3 (7.5% solution) (Merck) 
• 500µl Glutamine (Sigma #G7513) 
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• 4µl Heparin (50mg/ml solution) (Sigma #H3149-10KU) 
• 8µl FGF (Invitrogen) 
• 8µl EGF (1mg/ml solution) (Gibco #PHG0314) 
• 500µl Insulin-Transferrin-Selenium (Gibco #51500-056) 
• 9.6µl Putrescine (Sigma) 
• 4.62µl Progesterone (Sigma) 
• 0.2g BSA (Santa Cruz #sc-2323) 
 
4.1.3 Additional supplements for cell culture and assays:  
• Phosphate-Buffered Saline (PBS) (1 tablet in 200ml H2O) (Sigma #P4417-100TAB)  
• Trypsin/EDTA (1x)  
• Fixing solution: 3% Paraformaldehyde in PBS (Merck) 
• Blocking buffer: 0.5% BSA in DMEM F12 
• Washing buffer: 0.1% BSA in DMEM F12 
• Crystal violet stain: 5mg/ml in 2% ethanol (Sigma) 
• Toluidine blue stain: 1% in 50% isopropanol (Sigma) 
• Extraction solution: 2% SDS in H2O 
4.2 CELL COUNTING 
• Trypan Blue stain (Sigma) 
• Counting Slides (dual chamber)(Bio-Rad  #145-0011) 
4.3 MICROSCOPY  
• Permeabilisation solution/Buffer: 0.25% (v/v) of t-Octylphenoxypoly ethoxyethanol 
(TritonX-100) (#T-9289; Sigma) was dissolved in PBS/BSA. 
• F-actin cytoskeleton staining solution:  (1X Phalloidin conjugate working solution) 
1µl of 1000X Cyto-painter Phalloidin iFluor 488 Reagent (# ab176753; ABCAM ®) 
conjugate DMSO solution into 1ml PBS/BSA. 
• Nuclear stain: 4’,6-diamidino-2-phenylindole (DAPI) (#236276 ; Cell Biology 
Boehringer Mannheim , Germany) was received in a 10mg crystalized form and was 
dissolved in N,N-Dimethylformamide (DMF) to make up a stock solution of 5mg/ml. 
• DAPI working solution: 1µl of stock solution in 10ml PBS.  
4.4 SMALL MOLECULE INHIBITORS  
• Cyclopamine (BioVision #1578-5) 
• SANT-2 (WhiteSci #3617150)  
• Tomatidine (BioVision #1893-25) 
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4.5 ANTIBODIES 
Table 3: Different antibodies were used in the various analyses 
 
 
Cancer Stem Cell separation  
Primary Antibody 
(MACS Miltenyi) 
Microbeads (magnetic) conjugated to monoclonal anti-human 
CD133 antibodies (isotype: mouse IgG1, clone AC133).  
Flow cytometry 
Detection of CD133 
Primary Antibody 
(Biolegend)  
PE conjugated anti-mouse CD133 antibody (isotype: Rat 
IgG2a, clone 315-2C11)  
Fluorescence microscopy 
Detection of CD133 
Primary Antibody 
(MACS Miltenyi) 
CD133/1 (AC133) purehuman 
antibody (mouse monoclonal) 
1:400 
Secondary Antibody Alexa Fluor 532 anti-mouse IgG 
(Invitrogen) 
1:200 
Detection of c-Myc 
Primary antibody Mouse polyclonal IgG c-Myc (Abcam) 
Secondary antibody Alexa Fluor 660 anti-mouse IgG (Invitrogen) 
Detection of  KLF4 
Primary Antibody Rabbit polyclonal IgG KLF4 200µg/ml (Santa Cruz ) 
Secondary Antibody Alexa Fluor 594 anti-rabbit IgG (Invitrogen) 
Detection of Alkaline Phosphatase  
Primary Antibody Anti-human IgG Alkaline phosphatase γchain (sigma)  
Secondary Antibody Alexa Fluor 647 anti-goat IgG (Invitrogen) 
Detection of Shh 
Primary Antibody Rabbit polyclonal IgG (Abcam) 
Secondary Antibody Alexa Fluor 594 anti-rabbit IgG (Invitrogen) 
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5. METHODS 
5.1 CELL CULTURE 
The three cell lines were cultivated in the appropriate medium containing 
Penicillin/Streptomycin (10000 IU/ml), FCS (10%) and incubated at 37°C in 5% CO2  
(ThermoForm series ll water jacketed CO2 Incubator [HEPA FILTER])., using tissue culture 
treated dishes. The cell lines used were SW480, DLD1 and HT29 which represent early and 
middle to late stage colon cancer respectively. Cell lines were sub-cultured upon reaching 
confluency (approximately every 3-4 days), whereby media was aspirated off and cells rinsed 
with PBS. Thereafter 1ml Trypsin-EDTA was added to cells to facilitate detachment and cells 
were incubated for 5 minutes in the CO2 incubator. The resulting cell suspension was 
resuspended with 9ml media and an appropriate aliquot was placed into a new cell culture 
dish. Complete media was then added to the cells and they were returned to the incubator. 
5.1.1 Thawing of cells 
Frozen cells were removed from -80°C and thawed on ice. Thawed cells were transferred to a 
15 ml tube containing 5ml of the appropriate media supplemented with 1% 
Penicillin/Streptomycin and 20% FCS. This was then centrifuged at 800rpm for 5 minutes 
and the pellet re-suspended in the appropriate media. Each cell suspension was transferred to 
a cell culture dish and incubated at 37°C, 5% CO2. The growth of the cells was monitored 
over the next 5 hours and the media changed to 10% FCS upon cell attachment.   
5.1.2 Cryopreservation of cells 
The adherent cells were trypsinized and the resultant suspension centrifuged at 800rpm for 5 
minutes. The supernatant was discarded and the cell pellet re-suspended in the appropriate 
media supplemented with 1% Penicillin/Streptomycin, 20% FCS and 10% DMSO. 1ml of 
this solution was added to labelled cryovials and maintained at -20°C overnight; thereafter 
the vials were transferred to the -80°C freezer for long term storage. 
5.1.3 Determination of cell count 
A TC10 automated cell counter (Bio-Rad) was employed to determine the number of cells 
used in all experiments. 10µl of cell suspension (neat from trypsinized plate) was mixed with 
10µl of Trypan Blue dye in an Eppendorf tube. 10µl of this suspension was then carefully 
applied into a well on a dual chamber counting slide and inserted into the cell counter 
chamber. A total number of cells were determined as well as the number of live cells, this 
calculated as cells/ml and as a percentage of the total number of cells. 
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5.2 ISOLATION OF CSC’S FROM PARENT CANCER CELL POPULATION 
5.2.1 Magnetic Cell Separation 
Magnetic activated cell sorting allows cells to be separated following incubation with 
magnetic nanoparticles coated with antibodies against a particular surface antigen. In this 
study, the cell surface biomarker CD133 was used. The Miltenyi Biotec CD133 Cell Isolation 
kit was employed for magnetic separation (depicted in Figure 8).  
 
Figure 8: Basic principle of magnetic separation. Cells are first magnetically labelled and thereafter 
undergo magnetic separation whereby cells of interest remain in the column. The cells are then eluted 
from the column and collected for further experimentation (own figure).    
 
Prior to magnetic labelling, the cell number was determined by counting, with an optimal 
range of between 1x105 -1x106cells/ml. The cells were centrifuged at 800rpm for 10 minutes 
and the pellet then re-suspended in 300µl separation buffer: 2mmol EDTA, 0.5% BSA in 
PBS. 100µl of FcR Blocking Reagent was then added to this, together with 100µl of CD133 
MicroBeads; this was mixed well and incubated for 30 minutes at 4°C. Cells were then 
washed with 2ml separation buffer and centrifuged as before, but with the supernatant being 
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aspirated off and the cells finally re-suspended in 500µl of separation buffer. The separation 
column was placed within the magnetic field and prepared by rinsing with 500µl separation 
buffer; and once this had completely run through, the cell suspension was applied and the 
flow-through collected as the negative fraction. The column was washed 3 times with 500µl 
of separation buffer each time and this too was collected as part of the negative fraction. The 
column was removed from the magnetic field and placed into a Falcon tube, 1ml of 
separation buffer was added and immediately the plunger was firmly depressed to flush the 
magnetically labelled cells into the collecting tube. 
 
5.2.2 Flow cytometric confirmation of the isolated cell population 
 
Flow cytometry was employed to confirm the CSC population by the expression level of 
CD133 on the cell surface. The laser in the flow cytometer distinguishes between the labelled 
and unlabelled cells due to the fluorescence emitted by the dye. Positive and negative 
fractions eluted from the magnetic separation were evaluated for purity by flow cytometry. 
Both the positive and negative fractions were set to 1x106cells/100µl. 2µl of a conjugated 
antibody specific for CD133 (Miltenyi Biotech) was used and detected specifically using the 
FL2 laser, as it was tagged with a PE fluorochrome. Following a 20 minute incubation period 
in the dark, the cells were washed twice with separation buffer and finally re-suspended in 
100µl of buffer. Control mouse beads (BD CompBead Plus anti-mouse IgG κ) were also used 
with one drop of negative control added to each of the negative and positive beads, 
respectively; and with one drop of positive control solution added to positive beads. The 
positive beads were also incubated with 2µl of antibody for 20 minutes. The mouse beads 
were run first on the flow cytometer and the peaks obtained were used as a reference for the 
experimental samples and is used to optimize fluorescence compensation settings for 
multicolor flow cytometric analyses. Here, a shift in the peaks signifies a positive population 
that is able to emit fluorescence due to the presence of cell surface associated CD133. A 
linked marker was used to measure this shift in peaks, together with a dot plot to illustrate the 
percentage of cells that emitted fluorescence. This analysis represents the separation 
efficiency and therefore the purity of the CD133 positive fraction.  
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5.3 CELL IMPEDANCE ASSAYS 
These assays were carried out with the “xCELLigence” real time cell analyzer (RTCA) 
(Roche).The E-plates are coated with gold electrodes that detect impedance (resistance) as 
the cells attach and grow towards confluence. The cells in suspension are applied to these 
wells and the software set to perform sweeps every 30 minutes. Therefore a measurement of 
the resistance/attachment is made once the plates are loaded and thereafter every 30 minutes. 
An increase in measured resistance in each culture well indicates increased cell attachment 
and growth with the resistance measured as the cell index (CI). 
Optimization of cell densities 
Prior to evaluating experimental conditions, appropriate cell densities need to be determined 
for each cell line. The number of cells added to each well in the E-plates is crucial to the 
success of the experiment as there needed to be enough cells for them to reach confluency but 
not too many as confluency will be reached too quickly and fair assessment of the 
proliferative properties cannot be made. The number of cells added will differ between cell 
lines and types depending on their growth rate and the appropriate quantity can be determined 
using titration assays. The titration assay performed was according to the manufacturer’s 
guidelines and the following densities were recommended:  
• 6250 cells/ml  
• 12 500 cells/ml  
• 25 000 cells/ml 
• 50 000 cells/ml   
The cells were first washed with PBS and then trypsinized, the cell number was then 
determined using the Bio-Rad cell counter. The number of cells was adjusted by serial 
dilution in order to reach the optimal amount (this was optimized in another assay with 
varying cell quantities. The baseline was then calculated by adding 100µl of the appropriate 
media to each well that will be used and running this for 1 minute with 1 sweep. The 
subsequent steps were then programmed and 100µl of cell suspension added to the wells 
accordingly (total of 200µl per well), then left to stand for 30 minutes. The E-plate was then 
inserted into the xCELLigence instrument and the program set to run for 500 hours, 
performing a sweep every 30 minutes. This was stopped once the confluence plateau was 
reached. Plots were generated automatically by the RTCA software.  
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5.4 FLUORESCENCE MICROSCOPY 
Immunofluorescence is a technique which takes advantage of the highly specific binding of 
an antibody to its antigen in order to label particular proteins or other molecules within the 
cell. Cells are grown and then fixed on to coverslips prior to staining with a primary antibody, 
binding specifically to the protein or marker. This is then detected with a secondary antibody 
that is bound to a fluorophore and is referred to as indirect immunofluorescence. This 
complex fluoresces when excited with the correct excitation wavelength under the 
microscope, allowing for the visualization of the target proteins. This enables the precise sub-
cellular localization of proteins in relation to both the cytoplasm and the nucleus and allows 
one to elucidate likely interactions of proteins based on their localization. In this study, the 
products of the Myc and KLF4 genes will be analyzed as well as the marker alkaline 
phosphatase. 
Immunofluorescence staining of cells requires cell attachment and growth on sterile glass 
cover slips. CD133+ and CD133- cells of approximately 70% confluency were rinsed with 
PBS, trypsinized and thereafter re-suspended in the appropriate media. A heat sterilized glass 
cover slip was placed in a petri dish and the cell suspension was carefully aspirated only onto 
a cover slip, to ensure that the cells attached only to the cover slip. The plates were gently 
placed in an incubator at 37°C in a 5% humidified chamber overnight allowing the cells to 
attach to the cover slip. Following an overnight incubation at 37°C the slides were viewed, 
and more media was added if further incubation was required. Once the cells were partially 
confluent, the media was removed and the cover slips were rinsed with PBS before 500µl of 
3% paraformaldehyde (PFA) was added. Fixation was done for 30 minutes at room 
temperature, thereafter the PFA was removed, cover slips rinsed with PBS and once again 
placed in PBS, sealed with Parafilm® and stored at 4°C until staining. 
For immunofluorescence staining, the antibodies were diluted in PBS containing 0.5% BSA 
in PBS (BSA prevents non-specific binding to antigenic sites). The previously fixed cover 
slips were incubated with 100µl of the respective primary antibodies (see Table 3), at an 
optimised concentration of 1:400. Slides that were used as a negative staining control did not 
have primary antibody applied to them, instead 100 µl of the PBS/BSA solution was added. 
The slides were placed in container with a high moisture content provided by filter paper 
soaked in water, to reduce evaporation; and were incubated overnight at 4°C.This procedure 
provides sufficient time for the antibodies diluted at lower concentrations to identify and bind 
to their epitopes. Following primary antibody staining the cover slips were washed by 
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dipping 10 times in a beaker containing 0.5% PBS/BSA, followed by dipping 10 times in a 
second beaker of 0.5%PBS/BSA. The cover slips were placed on glass slides facing upward 
and 100µl of the secondary antibody solution (see table) was then applied and the slides once 
again incubated in a moist container in the dark for 1 hour. The negative control slides were 
only incubated with the secondary antibody and not the primary antibody. 
Further fluorescent staining was done in order to localise the nuclei and the actin 
cytoskeleton. The nuclei were stained with diamidino-phenylindole (DAPI-blue 
fluorescence), a fluorescent nucleic acid intercalator, which stains DNA and thus localises the 
nucleus. Slides were removed from the dark following secondary antibody staining and cover 
slips were rinsed in each of the 2 beakers of 0.5% PBS/BSA by dipping. 100µl of DAPI was 
applied to the cover slip and incubated for 5 min in the dark at room temperature.  
Phalloidin binds to F-actin filaments and allows for the cytoskeletal structure of the cell to be 
observed. Slides were once again rinsed in each of the 2 beakers following DAPI staining and 
100 µl of diluted Phalloidin488 was added and this was allowed to bind for 30 minutes in the 
dark. Finally the stained cover slips were then mounted on to slides (cell surface down) using 
Fluoromount® and this was left to dry for 2-3 hours at room temperature in the dark before 
viewing on the Zeiss LSM 780 confocal microscope. 
The captured images were then analysed using ImageJ software 1.47V where the cell of 
interest was first selected and the measurements set to include area, integrated density and 
mean grey value. Once this was determined the background fluorescence was measured 
thrice. Three cells within the region of interest were selected and measured and the CTCF 
(corrected total cell fluorescence) was then calculated according to the following formula: 
CTCF = Integrated density – (area of selected cell x mean fluorescence of background 
readings)  
These results are displayed in tables in the Results section 6.4.  
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5.5ASSAYS  
5.5.1Cell Adhesion assays 
To determine the ability of a certain cell line to adhere to a specific adhesive substrate, the 
adhesion assay was performed in 12 well plates coated with Geltrex™ (Invitrogen) (depicted 
in Figure 9). 250µl of the neat Geltrex™ solution is applied to wells and allowed to set at 
37ºC for 30 minutes in order to form a soft gel. The wells are then washed with 200µl of 
washing buffer and blocked with 200µl of blocking buffer for a further 30 minutes (see 
Materials section 4.1.3 for composition of buffers and solutions). To evaluate the efficacy of 
the Shh inhibitors, the cells were pre-incubated with the various small molecule inhibitors for 
10 minutes (see Materials section 4.4). The wells were then washed and the cells suspended 
in serum-free media were added to the wells at a concentration of 1x105 cells/ml and 
incubated for 2 hours. After 2 hours of incubation the attached cells were washed, fixed for 
10 minutes at room temperature, washed again and then stained with crystal violet for 10 
minutes. Following a thorough wash the plates were left to dry for 10 minutes and the dye 
was extracted with 1ml SDS solution and the absorbance measured at 550 nm. This 
absorbance acted as an indicator of cells attached to the Geltrex™ and the control wells were 
used to calibrate the spectrophotometer and set the reference point. The adhesion of CD133 
positive cells and CD133 negative cells was compared in terms of their ability to adhere to 
the Geltrex™ in this assay and was performed in triplicate. The adhesion potential of CSC’s 
is thought to be greater than that of differentiated cancer cells, and this was confirmed. 
Moreover, the ability of the small molecules to inhibit the attachment of CSC’s was also 
ascertained.  
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Figure 9: Basic principle of adhesion assay, whereby 1-3.)The ability of cells to adhere to wells 
coated with Geltrex™ (mimicking the ECM) is assessed and quantified following 3-4.) crystal violet 
staining and 5.) measurement by a spectrophotometer (own figure). 
 
5.5.2 Invasion assay 
The in vitro experimental approach to determine the potential of cells to invade an 
extracellular matrix (ECM) is the chemo-invasion assay. It makes use of a chemo-attractant 
on the lower site of a polycarbonate filter to induce cell invasion through an upper layer of 
extracellular matrix and subsequently through the pores of the filter membrane by chemotaxis 
(Figure 10). The pore size has to be large enough to allow for active cell ingression through 
the pores, but must not permit them to simply fall through. Geltrex™, the extracellular matrix 
which will be used contains components of the basement membrane, these mostly being 
laminin, collagen IV, and heparan sulfate proteoglycans. Prior to commencing the assay the 
cells were nutrient starved overnight using DMEM F12 with Penicllin/Streptomycin at a 
confluency of 70%. The following day the Transwell inserts were prepared by applying 50µl 
of neat Geltrex™ to each well and allowing this to set at 37ºC for 30 minutes. The cell 
suspension was then made up (concentration of approximately 1x106 cells/ml) by trypsinizing 
the cells and suspending them in the nutrient free media containing the small molecule 
inhibitors and allowing this to stand for 10 minutes. 300µl of CSC media (containing 
nutrients) was added to the lower chamber of the well while 100µl of the cell suspension was 
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added to the upper chamber. The upper chamber was then inserted into the lower chamber 
and this was incubated at 37ºC for 20 hours. Following incubation the media from the upper 
chamber was removed, then  rinsed with PBS and cells in the lower chamber were fixed with 
300µl of fixing solution for 15 minutes (with upper chamber inserted). Next, the lower 
chamber and insert were rinsed three times and 300µl of Toluidine Blue stain was added to 
the lower chamber (with upper chamber inserted) and left to stand for 2 minutes. The lower 
chamber and insert was rinsed once again and 1ml of SDS extraction solution was added and 
left for 1 hour. The extracted dye was then measured using a spectrophotometer set at 620nm 
relative to controls used to set the reference point. The effects of the small molecule 
inhibitors directed against the Shh pathway was assessed using this assay.  
 
Figure 10: Principle of invasion assay – 1.) Cell suspension applied to upper chamber with 
polycarbonate membrane coated with Getrex. This is then lowered into another chamber containing 
a chemo-attractant (nutrients).  2.) Cells invading transwell insert with membrane (8µm pore size) and 
Geltrex. This system serves as a model to mimic the interaction with the basement membrane. Cells 
with invasive potential are able to move through the pores and the Geltrex as they are drawn toward 
the chemo-attractant. 3.) Cells attached to the underside of the membrane are fixed with PFA and 
stained with Toluidine Blue. The dye extracted from attached cells is then measured at 620nm with a 
spectrophotometer (own figure).  
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5.5.3 Migration/Scratch assay 
Scratch/migration assays can be carried out in tissue culture to estimate the migration and 
proliferation rates of different cell types, as well as to evaluate the effect of potential 
inhibitors or promoters on cell proliferation. In this experiment the focus will be on the cell 
migration ability. These assays generally involve first growing a confluent cell monolayer 
within a cell culture plate (Figure 11). Next, a cell-free area is created by scoring a line 
through the confluent monolayer. The cells are then incubated with the test drug and a control 
in parallel. The closure of the open gap by cell migration and/or proliferation is then 
monitored microscopically over a 24 hour period (every 2 hours for the first 6 hours 
thereafter at the 24 hour mark). Ten measurements were made at each time interval and the 
average gap calculated. The rate at which the gap closes was then measured and used to 
determine the rate of migration following treatment with the small molecule inhibitors in 
comparison to the control. 
Figure 11: Basic principle of scratch/migration assay – 1.) Cell suspension placed on glass cover slip 
and incubated until, 2.) a confluent monolayer is grown . 3.) A line or scratch is scored through the 
monolayer. 4.) Closure of the gap is monitored over a 24 hour period with measurements of the gap 
taken periodically. 5.) The ability of cells to migrate or proliferate is measured, in some instances the 
gap closes completely while in others a gap remains (own figure). 
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5.6 STATISTICAL ANALYSIS 
 
Statistical evaluations of the following data were performed: 
 - Comparison of the expression of CD133 and other stem cell markers by positive and 
negative fractions using two-tailed Student’s t-test with a 95% confidence interval. p – values 
of less than 0.05 were considered significant.  
 
- The expression of Shh and CD133 following treatment with cyclopamine was compared to 
an untreated control using two-tailed Student’s t-test with a 95% confidence interval. p – 
values of less than 0.05 were considered significant.  
 
- Comparison of the positive and negative fractions in the adhesion assay using two-tailed 
Student’s t-test with a 95% confidence interval. p – values of less than 0.05 were considered 
significant. 
 
- Comparison of the treated and untreated cells in adhesion, invasion, and scratch assays: 
Upon application of the small molecule inhibitors, their effects on invasion and adhesion will 
be evaluated using a two-tailed Student’s t-test with a 95% confidence interval. p – values of 
less than 0.05 were considered significant. 
 
- Linear dependency between two variables was expressed using Pearson’s (r) correlation 
coefficient. The correlation between invasion and adhesion was determined, as well as the 
correlation between adhesion and migration (migration/scratch assay).  
 
 
 
32 
 
6. RESULTS 
6.1 FLOW CYTOMETRY CONFIRMATION ISOLATED OF CD133+ CELLS 
 
Flow cytometry was performed on a BD Accuri™ C6 flow cytometer following staining with 
a PE-conjugated CD133 antibody. Fluorescence was detected by the FL2 laser and using 
forward scatter plots cells were gated on the majority cell population using BD Accuri™ C6 
software. Outlying cells and debris were excluded and peaks were generated after counting 
10 000 cells. From the flow cytometry plots below, clear shifts in a specific cell population to 
the right (red peak) relative to the control (blue peak) are seen with both the DLD1 (Figure 
12.a) and HT29 (Figure 12.c) cell lines. The shift of 70% or more shows a successful 
magnetic separation of CD133+ cells from the general cell population. Increased purity of the 
CD133+ population is possible with a further magnetic separation. This was not employed in 
this situation since the specified CSC media would result in the selection and survival of 
CSC’s only. Due to the absence of FBS, differentiation of stem cells is discouraged. 
Furthermore, following the initial separation as a relatively low number of CD133+ cells are 
isolated, this would be an insufficient amount to perform another separation immediately 
without allowing the cells to proliferate. For successful isolation to be achieved, a minimum 
number of 1x108 cells/ml is recommended according to the manufacturer’s guidelines.  
 
 
Figure 12: CSC’s were successfully isolated using the CD133 receptor as a definitive marker. The 
Miltenyi Biotec CD133 Cell Isolation kit was employed for magnetic separation of cells; which was 
then confirmed by flow cytometry using a PE conjugated CD133 antibody. The blue peak represents 
the cells lacking CD133 expression, while the red peak represents those expressing CD133 on their 
cell surface. a.) DLD1 CSC’s with 73% of the population expressing CD133, b.) BD™ CompBeads 
Set Anti-Mouse Ig, κ/negative control compensation microparticles used to optimize fluorescence 
compensation settings, c.) HT29 CSC’s with a level of 70% cells expressing CD133.    
b.
 
c.
 
a.
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6.2 SPHEROID FORMATION OF CD133+ CELLS 
 
Following magnetic separation the CD133+ fractions were then cultured in a serum-free stem 
cell specific medium supplemented with various growth factors (see Materials section 4.1.2). 
The omission of FBS encourages stem cell growth without inducing differentiation. Initial 
cultures of separated stem cells grow as spheroids which were viewed in glass bottom cell 
culture dishes on the confocal microscope, using differential contrast microscopy (see images 
below Figure 13). This spheroid growth, a distinctive feature of stem cells, indicates the 
presence of CSC’s in these cultures.   
 
a.) DLD1  
 
b.) HT29  
Figure 13: CD133+ cells showed spheroid growth typical of stem cells, of a.) DLD1 CSC’s and b.) 
HT29 CSC’s. Each cluster of cells measures approximately 100μm in diameter. 
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6.3 CELL PROLIFERATION ASSAYS-  XCELLIGENCE 
Optimal cell concentrations are imperative in xCELLigence proliferation assays and these 
were determined in a prior experiment since studies using CD133+ fractions of DLD1 and 
HT29 cells are not mentioned in literature. Concentrations ranging from 6250 cells/ml to 50 
000 cells/ml were tested over a 100 hour period (Figure 14). This was in accordance with the 
manufacturer’s guidelines and the cell titration protocol provided by Roche. The duration 
over which the experiment should be conducted was also determined and is vital to the study 
since it should allow sufficient time for cells to reach confluence but not to become over-
confluent and detach. Another aspect taken into consideration was the limited volume the E-
plate well could accommodate (100μl) as this would restrict the amount of media that could 
be added. The volume of media had to be adequate for the duration of the experiment, to 
ensure cell survival. Furthermore, media could not be added during the course of the 
experiment as the weight of the newly added media distorts the impedance value, or the Cell 
Index (CI) as measured by the instrument.   
 
 
a.) 
b.) 
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Figure 14: Cell Index (level of adherence) was measured by xCELLigence using E-plates, with 
sweeps every 30 minutes over a period of 100 hours, giving an indication of cell growth patterns and 
proliferation rates. Dilution tests were performed using 50 000 (red), 25 000 (green), 12 500 (blue) 
and 6250 (pink) cells/ml. a.) HT29 CD133- dilution test, b.) HT29 CD133+ dilution test, c.) DLD1 
CD133- dilution test, d.) DLD1 CD133+ dilution test. From the graphs it can be deduced that the 
optimal concentration would be 25 000 cells/ml for CD133- fractions of both cell lines and 50 000 
cells/ml for CD133+ fractions of both cell lines. This deduction was made based on the overall curve 
of the graph and if an ideal level of confluence is reached in the stipulated time of 72 hours. It was 
also noted that the CD133- fractions were able to reach this level at approximately 48 hours, whereas 
the CD133+ fractions required an additional 24 hours, to reach confluence at 72 hours. Graphs shown 
represent the CI over time (hours).   
 
c.) 
d.) 
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Following optimization: 
 
a.) 
b.) c.) 
b.) 
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Figure 15: The optimal concentration previously determined was then used, 25 000 cells/ml CD133-  
and 50 000 cells/ml CD133+, which was performed in triplicate, shown here as the red, blue and 
green curves. a.) HT29   CD133- , b.) HT29   CD133+ , c.) DLD1   CD133- , d.) DLD1   CD133+. It 
was clear that the DLD1 cell growth pattern differed to HT29 pattern; and the DLD1 proliferation rate 
was slower than the HT29 cells. The CD133+ (CSC’s) proliferation rate was slower than CD133- 
cells, with growth plateaus at 72 hours and 48 hours, respectively. It could be suggested that the 
CD133+ fractions would either require further time or a higher concentration of cells in order to reach 
a greater level of confluence, as indicated from the dilution experiments. The HT29 CD133- cells 
exceeded previous CI recordings at this starting concentration by reaching a value of 0.75. This 
exponential growth pattern was evident in the dilution tests where CI peaked at a value of 1.1, 
representing a concentration of 50 000 cells/ml. A further observation that can be made is the decline 
in CI following the growth plateau of the CD133+ fractions of both cell lines, with a shorter plateau 
period in comparison to the CD133- fractions. A slight lag phase is also seen in the CD133+ fractions, 
particularly in the HT29 cell line.  
 
 
 
 
 
 
 
 
 
d.) 
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The HT29 CD133- exceeded previous CI recordings with a starting concentration of 25 000 
cells/ml by reaching 0.75. This exponential growth pattern was evident in the dilution tests 
where CI peaked 1.1 at a concentration of 50 000 cells/ml (Figure 15). These HT29 non-CSC 
showed highly exponential growth in the first 7 hours, followed by further growth at a 
slightly lower rate in the subsequent 14 hours. After this, a plateau was then reached and the 
CI ranged between 0.6 and 0.7. This indicates that the HT29 cell line has a greater 
proliferation rate in comparison to the DLD1 cell line. In contrast the CSC of the same cell 
line showed a far less rapid growth over the initial 21 hour period, resulting in a plateau 
between 0.1 and 0.2 CI. Similarly, the DLD1non-CSC showed accelerated growth in the first 
7 hours, followed by further growth till reaching a plateau at 14 hours; however, the CI 
reached a maximum of merely 0.35. As expected, the CSC counterpart subsequent to a 21 
hour exponential growth phase, reached a plateau of 0.2 CI (please note that CI values given 
are approximate and provide an indication of average of 3 measurements). A further 
observation that can be made is the decline in CI following the plateau of the CD133+ 
fractions of both cell lines, with a shorter plateau period in comparison to the CD133- 
fractions. A slight lag phase is also seen in the CD133+ fractions, particularly in the HT29 
cell line, this possibly being due to cancer stem cells being slow cycling99. Overall the trends 
noted are that the DLD1 cell line has a slower growth rate than that of the HT29 cell line and 
that in both cell lines the CSC’s proved to have slower proliferation rates in comparison to 
their non-CSC counterparts. It could be suggested that the CD133+ fractions would either 
require further time or a higher starting concentration of cells in order to reach a greater level 
of confluency, as can be deduced from the dilution experiments. 
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6.4 CONFOCAL MICROSCOPY CHARACTERIZATION 
The positive and negative fractions collected from the magnetic separation using the marker 
CD133 were then further characterized using confocal microscopy. Several markers were 
selected based on their role in the Shh pathway, invasion and metastasis. These markers 
included c-Myc, KLF4 and alkaline phosphatase and are also thought to be indicators of 
stem-like capacity required for induced pluripotent stem cell production and are markers of 
embryonic stem cells. Positive and negative fractions were stained with primary antibodies 
specific for the respective marker and thereafter stained with secondary antibodies with 
conjugated fluorochromes. In the case of negative control slides the primary antibody was 
omitted and only secondary staining was performed to differentiate from non-specific 
binding. Fluorescence microscopy captured on Zeiss confocal microscope at 63X 
magnification provided an indication of the expression of cell surface markers.Using the 
confocal microscope the fluorescence was captured with Zeiss software (Carl Zeiss LSM 
780), image gain was adjusted within certain bounds. The images were analyzed using 
ImageJ software in order to quantify the fluorescence emitted and 3 cells per captured field of 
view were selected for measurement. The CTCF was then calculated with the measured 
background fluorescence taken into consideration (see Methods section 5.4 for formula). The 
nuclei were stained with the DNA intercalating dye DAPI (blue), and f-actin filaments were 
stained with Phalloidin 488 to stain the cytoskeleton green. The respective antibody staining 
is indicated with red fluorescence. The three stains are shown separately as well as a final 
image overlaying them in order to visualize where the marker expression in relation to the 
cytoskeleton and nucleus as well as the number of cells and their orientation.  
See Appendix B for all negative control images.   
6.4.1 CD133 localization in non-permeabilized CD133+ and CD133- cell fractions 
 
At the outset, CD133 expression was evaluated whereby fluorescence emitted from the 
positive fractions of both the DLD1 and HT29 cell lines was observed to be far greater than 
that of the negative cell fractions. This was to be expected since isolation of the CSC’s was 
done on the basis of this marker and cells not expressing CD133 would have passed through 
the column to comprise of the negative fraction.  
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a.) DLD1 
 CD133+  
  
 
 
 
 
 
 
 
 
 
 
 
Control 
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CD133-   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: CD133 localization in non-permeabilized CD133+ and CD133- fractions of DLD1 cell line 
at 63x magnification with nuclei shown with (n) and debris (D). Arrows indicating the cell-surface 
CD133 on DLD1 cells. It is evident that the levels of CD133 are far higher in the DLD1 CD133+ cell 
fraction with no expression of CD133 seen in the negative fraction (Original Magnification 63X).  
 
Table 4: Corrected Total Cell Fluorescence (CTCF) of  DLD1 CD133+ cells (non-
permeabilized), stained with an anti-CD133 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence  
CTCF 
 20279 1086 0.405 19839.17 
 19842 1776 0.405 19122.72 
 21985 1678 0.405 21305.41 
Average CTCF    20089.1 
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Table 5: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells ( non-
permeabilized); negative control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1435 1025 0 1435 
 1652 895 0 1652 
 1524 939 0 1524 
Average CTCF    1537 
 
 
Table 6: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells (non-
permeabilized), stained with an anti-CD133 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 4852 1296 1.387 3054.448 
 4751 1485 1.387 2691.305 
 4683 1346 1.387 2816.098 
Average CTCF    2853.95 
 
 
 
b.) HT29  
 CD133+  
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b.) CD133-
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 17: b.) CD133 localization in non-permeabilized CD133+ and CD133- fractions of HT29 cell 
line, nuclei shown with (n) and cell undergoing apoptosis (A). In non-permeabilized HT29 cells the 
CD133+ fraction displayed a greater fluorescence intensity indicated with arrows, in comparison to 
the CD133- fraction, which had little or no fluorescence when stained with the CD133 antibody 
(Original Magnification 63X). 
Table 7: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells (non-
permeabilized), stained with an anti-CD133 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 9963 639 0.169 9855.009 
 10308 629 0.169 10201.7 
 8805 661 0.169 8693.291 
Average CTCF    9583.333 
Table 8: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells(non-
permeabilized), stained with an anti-CD133 antibody  
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 2068 571 0.386 1847.594 
 2099 507 0.386 1903.298 
 2263 667 0.386 2005.538 
Average CTCF    1918.81 
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6.4.2 CD133 localization in permeabilized CD133+ and CD133- cell fractions 
a.) DLD1 
 CD133+ 
 
 
 
 
 
 
 
 
 
  
CD133- 
 
 
 
 
 
 
 
 
 
 
Figure 18: a.) CD133 localization in permeablized CD133+ and CD133- fractions of DLD1 cell line, 
nuclei indicated with (n). With the permeabilization of DLD1 cells, CD133 is additionally localized 
intracellularly within the CD133+ fraction. Based on the colour of the nucleus in the 2D image, pink, 
this indicates a co-staining of the nucleus (red+blue=pink), shown with arrows, indicating an 
association of CD133 with the nucleus or DNA. Although some fluorescence is visible in the CD133-  
cell fraction indicated with the arrow, it is to a much lesser extent (Original Magnification 63X).  
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Table 9: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells 
(permeabilized), stained with an anti-CD133 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 12003 1948 0.054 11897.81 
 13801 1517 0.054 13719.08 
 12448 1577 0.054 12362.84 
Average CTCF    12659.91 
 
 
Table 10: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells 
(permeabilized), stained with an anti-CD133 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 608 237 0.512 486.656 
 658 430 0.512 437.84 
 733 354 0.512 551.752 
Average CTCF    492.0827 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
b.) HT29  
CD133+  
 
 
 
 
 
 
 
 
 
 
CD133-  
 
 
 
 
 
 
 
 
 
 
Figure 19: b.) CD133 localization in permeabilized CD133+ and CD133- fractions of HT29 cell line, 
nuclei indicated with (n) and background fluorescence (BF).  CD133 was detected in the cytoplasm of 
CD133+ cells shown with arrows. The receptor seemed to be concentrated in some areas of the cell 
producing a more intense fluorescence emission- cytoplasmic and nuclear association. Nuclear 
association is apparent with pink colouration, shown with arrows.  A low level of CD133 was 
detected in the cytoplasm of the CD133- cells indicated with the arrow. It is far les prominent in 
comparison to the CD133+ cells (Original Magnification 63X).  
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Table 11: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells 
(permeabilized), stained with an anti-CD133 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 9216 791 0.15 9097.35 
 10401 811 0.15 10279.35 
 10250 927 0.15 10110.95 
Average CTCF    9829.217 
 
Table 12: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells 
(permeabilized), stained with an anti-CD133 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 342 108 0.02 339.84 
 399 181 0.02 395.38 
 422 365 0.02 414.7 
Average CTCF    383.3067 
 
 
Figure 20:  Graph summarizing the CD133 expression of separated cell fractions in non-
permeabilized (surface expression) and permeabilized (cytoplasmic expression) cells derived from the 
DLD1 and HT29 cell lines. Significantly increased level of CD133 expression is seen in the CD133+ 
fractions of both cell lines of non-permeabilized cells with a relative fluorescence peaking at 
approximately 20 000 units in DLD1 non-permeabilized cells (p= 0.0014**). The lowest expression 
level of CD133 positive cells was seen on the cell surface of HT29 (non-permeabilized) cells (p= 
0.0042**). A significant difference in the expression of CD133 in the permeabilized cells is also 
noted in both the DLD1 (p= 0.0022**) and HT29 cells (p= 0.0014**).  
 
 
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
22000
Re
la
tiv
e 
flu
or
es
ce
nc
e 
(a
rb
itr
ar
y 
un
its
) 
CD133 expression of separated fractions 
CD133 positive
CD133 negative
48 
 
DLD1 CD133+ cells  non-permeabilized and permeabilized Z-stack 
a.) Non-permeabilized  
 
 
 
 
 
 
 
 
 
 
b.) Permeabilized  
 
 
 
 
 
 
 
 
 
 
 
Figure 21: The Z-stack images show the expression of CD133 in non-permeabilized and 
permeabilized CD133 positive fractions of DLD1 cells. a.) Arrows indicate the nuclei (n) which 
appear blue and cell surface staining of CD133 (CSS) appears red. b.) When permeabilized CD133 is 
detected in the cytoplasm (CS) as well as the cell surface (CSS) it can be seen in the images as pink 
and red respectively (Original Magnification 63X). 
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HT29 CD133+ cells  non-permeabilized and permeabilized Z-stack 
a.) Non-permeabilized  
b.) Permeabilized  
Figure 22: Z-stack images of non-permeabilized versus permeabilized HT29 CD133+ cells. a.) Nuclei 
are shown with (n) and arrows indicate the cell surface staining (CSS) which appears red. b.) A 
definite presence of CD133 is identified in the cytoplasm (CS) of the cells shown as pink (Original 
Magnification 63X).    
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The results above indicate that CD133 is strongly expressed by the CD133+ fractions of both 
the DLD1 and HT29 cell line (Figure 16-22). In the non-permeabilized cells the cell surface 
expression of CD133 is clearly evident.The permeabilized CD133+ cells of both cell lines 
stained with a CD133 antibody show a nuclear association with the protein. Permeabilized 
cells indicate the presence of CD133 in both the CD133+ and CD133- within the cytoplasm. 
Z-stack images were captured to confirm the cell surface expression of CD133 where the 
non-permeabilized CSC’s did not display fluorescence in the cytoplasm but expression of 
CD133 is seen on the cell surface (red) as expected and the permeabilized fraction showed 
fluorescence on the cell surface as well as the cytoplasm (blue nuclei+red stain = pink). This 
localization is in accordance with the initial cell separation step as cells within this population 
were isolated based on their cell surface expression of CD133. Furthermore, it shows that 
CD133 is not only expressed on the cell surface, is also synthesized within the cell and due to 
the pink fluorescence an association with the nucleus is suggested.  
 
6.4.3 Immunofluorescence localization of c-Myc in CD133+ and CD133- cells 
a.)DLD1 
 CD133+   
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CD133-   
   
  
 
 
 
 
 
 
 
 
 
 
Figure 23: a.)Expression of c-Myc in CD133+ and CD133- fractions of DLD1 cell line; nulcei 
shown with (n). From the above images a subtle difference between DLD1 CD133+ and DLD1 
CD133- is apparent. Both fractions showed cytoplasmic staining, often being associated with 
membrane protrusions in CD133+ cells (arrow). However, not all CD133+ cells showed 
consistent staining, instead a few cells within the population stained more intensely (Original 
Magnification 63X).  
 
Table 13: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells that were 
stained with an anti-C-myc antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1979 599 0.737 1537.537 
 2615 697 0.737 2101.311 
 2300 673 0.737 1803.999 
Average CTCF    1814.282 
 
Table 14: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells, stained 
with an anti-C-myc antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1169 480 0.106 1118.12 
 1219 663 0.106 1148.722 
 1244 533 0.106 1187.502 
Average CTCF    1151.448 
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b.) HT29  
CD133+   
   
 
 
 
 
 
 
 
 
 
 
CD133-  
   
   
 
 
 
 
 
 
 
 
 
Figure 24: b.) Expression of c-Myc in CD133+ and CD133- fractions of the HT29 cell line; nuclei 
shown with (n) and cell undegoing apoptosis with (A). In comparison to the DLD1 cell line a more 
definite differentiation betweeen the CD133+ and the CD133- fractions can be made here. 
Furthermore, selected HT29 CD133+ cells emitted a more concentrated fluorescence. Fluorescence 
seen in negative fraction could be attributed to weak background fluorescence (BF) (Original 
Magnification 63X).  
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Table 15: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells, stained 
with an anti-c-Myc antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 3358 1244 0.013 3341.828 
 3488 799 0.013 3477.613 
 3604 583 0.013 3596.421 
Average CTCF    3471.954 
 
 
Table 16: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells, stained 
with an anti-c-Myc antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1578 601 0.009 1572.591 
 1614 764 0.009 1607.124 
 1521 546 0.009 1516.086 
Average CTCF    1565.267 
 
 
Figure 25:  Summary of the c-Myc expression in the  DLD1 and HT29 cell lines. A non-significant 
difference in relative fluorescence is noted in the DLD1 cell line (p= 0.051), whilst a highly 
significant difference in c-Myc expression is seen in the HT29 cell line (p= 0.0003***).  
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6.4.4 Immunofluorescence localization of KLF4 in CD133+ and CD133- cells 
a.) DLD1 
 CD133+   
   
  
 
 
 
 
 
 
 
 
CD133- 
    
  
 
 
 
 
 
 
 
 
Figure 26: a.) Expression of KLF4 in CD133+ and CD133- fractions of DLD1 cell line; nuclei shown 
with (n).  The zinc-finger transcription factor KLF4 is expressed by both DLD1 CD133+ as well as 
DLD1 CD133- cells. The intensity in the positive fraction is greater than in the negative fraction with 
a distinct punctuate perinuclear staining pattern seen in both. An area of non-specific binding is also 
visible (NSB). In addition, some fluorescence is observed in the control slide of the CD133- fraction 
(see Appendix B), suggesting the possibility of non-specific binding. This background fluorescence 
was subtracted upon calculation of the CTCF value (Original Magnification 63X).  
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Table 17: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells, stained 
with an anti-KLF4 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 7727 438 0.067 7697.654 
 7054 378 0.067 7028.674 
 6472 670 0.067 6427.11 
Average CTCF    7051.146 
 
 
Table 18: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells, stained 
with an anti-KLF4 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 4351 860 0.662 3781.68 
 4458 702 0.662 3993.276 
 4118 1018 0.662 3444.084 
Average CTCF    3739.68 
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b.) HT29 
 CD133+   
   
   
   
 
 
 
 
 
 
 
 
CD133- 
 
   
    
 
 
 
 
 
 
 
Figure 27: b.) Expression of KLF4 in CD133+ and CD133- fractions of HT29 cell line, nuclei shown 
with (n). Although the fluorescence intensity appears similar in both the CD133+ and CD133- 
fractions distinctly brighter fluorescence is visible in the CD133+ fraction, with only smaller areas of 
fluorescence visible in the negative fraction. Arrows indicate the nucleosomal association of KLF4 in 
the CD133+ fraction. Once again the staining forms a punctate pattern and is perinuclear and not 
nucleosomal. The bright spot seen in the CD133- fraction indicated with an arrow is non-specific 
binding (NSB) and was excluded in the integrated density measurements, to avoid an outlier that may 
skew the final CTCF value (Original Magnification 63X).  
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Table 19: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells, stained 
with an anti-KLF4 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 13648 1141 0.72 12826.48 
 14613 915 0.72 13954.2 
 13042 1237 0.72 12151.36 
Average CTCF    12977.35 
 
Table 20: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells, stained 
with an anti-KLF4 antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1707 391 0.117 1661.253 
 1676 557 0.117 1610.831 
 1633 807 0.117 1538.581 
Average CTCF    1603.555 
 
 
Figure 28: Bar graph summarizing KLF4 expression in DLD1 and HT29 cell lines. The expression of 
KLF4 is significantly increased in CD133+ fractions of both the DLD1 (p= 0.0031**) and HT29 (p= 
0.0295*) cell lines. Following measurement of the integrated density and calculation of the CTCF, a 
greater difference in relative fluorescence associated with the HT29 cell line.  
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6.4.5 Immunofluorescence localization of alkaline phosphatase in CD133+ and CD133- 
cells 
a.) DLD1 
 CD133+  
   
  
 
 
 
 
 
 
 
 
CD133- 
   
    
 
 
 
 
 
 
 
Figure 29: a.) Expression of alkaline phosphatase in CD133+ and CD133- fractions of the 
DLD1 cell line, nuclei shown with (n) and apoptosis (A).  Localization is perinuclear with more 
intense areas possibly associated with the trans – Golgi network. The punctate staining may be 
cell surface related as alkaline phosphatase is secreted onto the cell surface as well as 
extracellularly.  Flecks of fluorescence, shown with arrows, are also seen surrounding the 
CD133+ cells. A far lower level of expression is noted in the CD133- fraction and could 
perhaps represent a low level of cell membrane associated alkaline phosphatase (Original 
Magnification 63X).  
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Table 21: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells, stained 
with an anti-alkaline phosphatase antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 16774 1480 0.207 16467.64 
 16523 1557 0.207 16200.7 
 17563 1765 0.207 17197.65 
Average CTCF    16622 
 
 
Table 22: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells, stained 
with an anti-alkaline phosphatase antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1119 499 0.134 1052.134 
 1085 396 0.134 1031.936 
 1018 749 0.134 917.634 
Average CTCF    1000.568 
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b.) HT29 
 CD133+   
    
     
 
 
 
 
 
 
 
 
CD133- 
  
 
    
  
 
 
 
 
 
 
Figure 30: b.) Expression of alkaline phosphatase in CD133+ and CD133- fractions of HT29 cell line; 
nuclei shown with (n) and apoptosis (A). Increased fluorescence intensity is evident on the cell 
surface of the CD133+ fraction of the HT29 cell line. Punctate staining for alkaline phosphatase is 
present in extracellular spaces. A far lower level of expression is seen in the CD133- fraction. Despite 
extracellular detection of alkaline phosphatase than in the CD133- fraction, it is far less prominent 
than the CD133+ fraction (Original Magnification 63X).  
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Table 23: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells, stained 
with an anti-alkaline phosphatase antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 20701 1497 0.327 20211.48 
 20595 1866 0.327 19984.82 
 19289 1476 0.327 18806.35 
Average CTCF    19667.55 
 
Table 24: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells, stained 
with an anti-alkaline phosphatase antibody 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1940 553 0.47 1680.09 
 1976 790 0.47 1604.7 
 1911 670 0.47 1596.1 
Average CTCF    1626.963 
 
 
Figure 31: Bar graph representing alkaline phosphatase expression in DLD1 and HT29 cell lines. 
Alkaline phosphatase staining clearly differentiated between CD133 positive and CD133 negative 
fractions of DLD1 (p= 0.0354*) and HT29 cells (p= 0.0380*), respectively. There is a significant 
difference (p< 0.05) in relative fluorescence between the two cell populations of both cell lines.  
 
Overall the expression of CSC markers c-Myc, KLF4 and alkaline phosphatase was found to 
be increased in both the DLD1 and HT29 CD133+ fractions (Figure 23- 31). In most cases 
this increase was calculated to be significantly higher than that of the CD133- fraction except 
for the expression of c-Myc in the DLD1 cell line.  
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6.5 CELL ADHESION ASSAYS 
The adhesion to extracellular matrix proteins is vital for the invasion of neoplastic cells. 
The ability of CD133+ cells to adhere was compared to CD133- cells using cell adhesion 
assays (Figure 32). Thereafter the potential of the Shh small molecule inhibitors 
cyclopamine and SANT-2 or the control molecule tomatidine, to impede this binding 
was evaluated (Figure 33-36). Cell adhesion to Geltrex™ (containing components of the 
ECM) was determined following incubation with the small molecule inhibitors. Cells 
were transferred to a 96-well plate, either coated with Geltrex™ or uncoated, for 2 hours 
at 37°C. Attached cells were fixed, stained with crystal violet and absorbance was 
measured at 550 nm. The attachment of cells to the uncoated control plate represents the 
background binding. The absorbance of the stain present in the coated plates correlates 
directly with the percentage of Geltrex™-attached cells.  Data are representative of 
experiments carried out in triplicate.  
Figure 32: Bar graph representing cell adhesion to Geltrex™. A significantly increased adhesion 
potential was noted in both the CD133+ fractions (light grey) of DLD1 (p= 0.0028**) and HT29 (p= 
0.0006***) cell lines, in comparison to the negative fractions (dark grey). This indicates the enhanced 
ability of CSC’s to adhere, a key step in the process of metastasis. Experiments were carried out in 
triplicate. 
** *** 
 
63 
 
2.38
2.385
2.39
2.395
2.4
2.405
2.41
2.415
2.42
2.425
2.43
DLD1 + cells DLD1+ cells with
drug
HT29+ cells HT29+ cells with drug
A
bs
or
ba
nc
e 
(5
50
nm
) 
Effect of SANT-2 (2µM) on cell adhesion in CD133+ 
 DLD1 and HT29 cells 
2.65
2.66
2.67
2.68
2.69
2.7
2.71
2.72
2.73
2.74
2.75
DLD1+ cells DLD1+ cells with
drug
HT29+ cells HT29+ cells with drug
A
bs
or
ba
nc
e 
(5
50
nm
) 
Effect of cyclopamine (2µM) on cell adhesion in CD133+ 
DLD1 and HT29 cells  
 
Figure 33: Bar graph representing the effects of cyclopamine on cell adhesion.Treatment with 2µM 
cyclopamine resulted in a marked reduction in the adhesion potential of both DLD1 CSC’s (p= 
0.0020**) and HT29 CSC’s (p= 0.0025**) in comparison to untreated cells following a 2 hour 
incubation.  
Figure 34: Bar graph representing the effects of SANT-2 on cell adhesion. No significant decrease in 
adhesion potential was seen after 2µM of SANT-2 treatment. In both cell lines an unusually increased 
level of adhesive ability was noted in comparison to the untreated cells. The results obtained do 
suggest that at a concentration of 2µM SANT-2 would be ineffective in impeding cell adhesion in 
both the DLD1 and HT29 cell lines.  
** ** 
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Figure 35: Bar graph representing the dose-dependent effects of SANT-2 on cell adhesion. A dose-
dependency assay demonstrated that at higher concentrations SANT-2 had a more significant effect 
on cell adhesion of both DLD1 (dark grey) and HT29 (light grey) CSC’s. A 5-fold increase in 
concentration resulted in a significantly decreased adhesion (DLD1 p= 0.0007***, HT29 p= 
0.0020**) while a further reduction was seen with a 10-fold increase in concentration (in comparison 
to untreated controls) (DLD1 p= 0.0001***,  HT29  p= 0.0001***). Subsequently in further 
experiments, the concentration of 20µM was then utilized in treating cells.  
 
Figure 36: Bar graph representing the effects of the inert cyclopamine analogue, tomatidine on cell 
adhesion. No significant changes in adhesion potential are apparent following treatment with 
tomatidine at a concentration of 2µM. Neither the DLD1 (p= 0.2301) nor the HT29 (p= 0.2354) cell 
lines were affected by this analogue. 
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6.6 CELL INVASION ASSAYS 
 
The experimental approach to determine the potential of cells to invade an 
extracellular matrix (ECM) is the chemo-invasion assay. It makes use of a 
polycarbonate filter to facilitate cell invasion through an extracellular matrix 
(Geltrex™) containing the protein laminin. The cells are stimulated to migrate 
through the Geltrex™ coated membrane by a chemoattractant, this usually being 
nutrients contained in culture medium. The invasion assays were performed using the 
aforementioned neoplastic cell lines to evaluate the ability of the Shh small molecule 
inhibitors to hinder cell invasion. Prior to commencing each assay, cells were pre-
incubated with one of either cyclopamine (2µM), SANT-2 (20µM) or tomatidine 
(2µM). Cells that were able to actively penetrate the membrane and attach to the 
underside within the 20 hour incubation time were fixed and stained with Toluidine 
Blue. Once extracted from the cells the absorbance of the dye was measured at 
620nm.; where increasing absorbancy was directly associated with increases in the 
number of invasive cells (Figure 37-39). The assays were performed in triplicate and 
the background absorbance excluded. 
Figure 37: Bar graph representing the effect of cyclopamine on the invasive potential of CD133+ 
DLD1 and HT29 cells.  With cyclopamine treatment (2µM), the invasive ability of both DLD1 (p= 
0.0205*) and HT29 (p= 0.0122*) cell lines was significantly decreased. Both cell lines responded 
similarly to the drug.  
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Figure 38: Bar graph representing the effect of SANT-2 on the invasive potential of CD133+ DLD1 
and HT29 cells.  The synthetic analogue molecule SANT-2 at a concentration of 20µM had a similar 
inhibitory effect to cyclopamine and was found to significantly impede the invasive capabilities of 
both DLD1 (p= 0.0117*) as well as HT29 (p= 0.0021**) CSC’s, respectively.   
Figure 39: Bar graph representing the effects of the inert cyclopamine analogue, tomatidine on cell 
invasion.The control molecule tomatidine (2µM) had no significant effect on the invasive potential of 
DLD1 (p=  0.5286) and HT29 (p=  0.7460) CSC’s, respectively. Interestingly, the overall invasive 
potential of HT29 CSC’s proved to be lower than that of DLD1 CSC’s.  
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6.7 CELL MIGRATION/SCRATCH ASSAYS 
 
Cell migration or scratch assays were performed to ascertain the potential effect that a Shh 
inhibitor could have on cell migration. This was done by creating a cell-free area in a 
confluent monolayer of cells and monitoring gap closure by means of differential interference 
contrast (DIC) microscopy, over a 24 hour period. An initial experiment was performed using 
a 500µl micropipette tip to form the scratch and the gap closure was assessed at time 0, 6 
hours and 24 hours (See Appendix C). It was found that the gap was too wide to obtain 
accurate measurements, and furthermore the cells seemed to have some difficulty recovering 
from a wound to that extent. It was also observed that much growth/migration occurred 
between the start time and the first measurement time of 6 hours.  Subsequently, a smaller 
diameter sterile 200µl micropipette tip was used to score through the confluent cell 
monolayer to generate a cell-free area for assessment of cell migration over a 24 hour period; 
and these findings are presented below. Based on the results of the cell adhesion assays for 
the purposes of cell migration, only the CD133+ cells were evaluated here, since CD133+ 
cells proved to have enhanced adhesion ability.  
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Cyclopamine treatment of migrating cells:  
a.) DLD1 CD133+ cells, no treatment control 
  0 hours    2 hours    4 hours  
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b.) DLD1 CD133+  cells, treated with cyclopamine 
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Figure 40: DIC images were captured every 2 hours for first 6 hours, with a final measurement at 24 
hours. a.) DLD1 CD133+ cells show steady cell growth and gap closure over the 6 hour period and 
almost complete closure after 24 hours. b.) The addition of cyclopamine appears to slow gap closure 
within first 6 hours. c.) Change in scratch diameter illustrated graphically, with an increase in scratch 
width in first 6 hours due to cyclopamine treatment. Thereafter normal growth is seen and the width is 
similar to that of the control after 24 hours of incubation. d.) Bar graph representing cell migration 
(µM) over a 24 hour period. The difference in scratch diameter peaking in the period of 6 to 24 hours 
despite the application of cyclopamine. The control shows steady gap closure throughout the 6 hour 
period (Original Magnification 20X).  
 
 
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
230
0 2 4 6 24
W
id
th
  (
µm
) 
Time (hours) 
Graphical representation of cell migration over 24 hours 
DLD1 control
DLD1 + 2µM cyclopamine
70 
 
a.) HT29 CD133+ cells, no treatment control  
0 hours    2 hours    4 hours  
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b.) HT29 CD133+ cells, treated with cyclopamine 
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c.)  
 
d.)  
 
Figure 41: HT29 CSC’s treated with cyclopamine indicated a similar reaction to the DLD1 cell line, 
a.) the control displayed consistent gap closure over the 24 hour period, b.) However, a definite 
hindrance in closure was seen with the addition of cyclopamine particularly during the first 6 hours. 
c.) The effect of the small molecule inhibitor is visible graphically where the scratch actually 
increased in width before closing at the 6 hour mark, the steady growth of the control is seen with the 
linear decrease in diameter. d.) bar graph illustrating the sudden growth/migration of the cells exposed 
to cyclopamine during the 4 to 6 hour period in contrast to the growth throughout the 24 hour 
incubation of the control (Original Magnification 20X).  
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SANT-2 treatment of migrating cells:  
a.) DLD1 CD133+ cells; no treatment control  
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b.) DLD1 CD133+  cells, treated with SANT-2  
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Figure 42: DLD1 CSC’s responded differently to SANT-2 treatment as compared to cyclopamine. a.)  
The early observations showed an initial phase of cell migration and closure of the cell-free area from 
time 0 to 2 hours, followed by a seeming stabilization of migration and maintenance of a constant 
width. However, an almost complete closure of the gap was reached at the end of the 24 hour period. 
b.) When exposed to SANT-2 the width of the scratch did not appear to change much. c.) From the 
graph it can be noted that despite both scratch widths beginning at approximately the same point, their 
end width differs significantly. An initial growth is seen in both the DLD1 CSC’s treated with SANT-
2 as well as the control, with almost a plateau of growth visible with both once again. A final growth 
spurt results in the gap almost closing in the control; while conversely a gap still remains on the 
experimental slide. d.) Bar graph representing the early and late growth surges experienced by both 
the control and the DLD1 cells exposed to SANT-2 (Original Magnification 20X).  
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a.) HT29 CD133+ cells; no treatment control  
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b.) HT29 CD133+ cells, treated with SANT-2  
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Figure 43: The HT29 cell line shows an almost identical pattern when treated with SANT-2, a.) The 
control scratch began closing within the first 2 hours, appeared to lag after which gap closure resumed 
until near closure. b.) The same trend occurred with the cells that were incubated with SANT-2; 
however the gap remained clearly apparent even after 24 hours. c.) The preliminary scratch width 
decrease in both the experimental slide as well as the control, the stabilization of closure during the 2 
to 6 hour period and the final accelerated closure prior to reaching the end of the 24 hour incubation. 
Notably, the final width point remains distinctly higher in the HT29 CSC’s with SANT-2 treatment. 
d.) Bar graph showing that most growth occurred during the first two hours of incubation and prior to 
the final 24 hour measurement (Original Magnification 20X).   
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DLD1 CD133+  
    Untreated            Treated with 20µM SANT-2  
 
HT29 CD133+  
  Untreated               Treated with 20µM SANT-2  
 
Figure 44: Fluorescence staining of CD133+ DLD1 and HT29 cells after treatment with SANT-2. 
Following F-actin staining with Phalloidin 488 (green) and nuclear staining with DAPI (blue) the 
difference in scratch width is clearly visible. Pharmacological treatment with SANT-2 clearly retarded 
cell migration into the cell free areas in both DLD1 and HT29 CSCs (Original Magnification 20X). 
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Tomatidine treatment of migrating cells: 
a.) DLD1 CD133+ cells, no treatment control  
    0 hours            2 hours             4 hours  
 
 
 
 
 
      6 hours     24 hours  
 
 
 
 
 
b.) DLD1 CD133+ cells, treated with tomatidine 
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Figure 45: With the inclusion of the control molecule tomatidine DLD1 CSC’s appeared to undergo 
unimpeded cell migration. a.) Closure of the gap in the no treatment control, as well as the slide 
treated with b.) tomatidine occurred steadily throughout the 24 hour incubation time. The final images 
captured illustrate an almost virtual gap closure in both. c.) Both the experimental and control slide 
had approximately the same start and end point scratch width, with linear growth indicated by the 
steady decrease in width. d.) Bar graph showing the difference in scratch diameter. It appears to be 
almost identical in both the experimental and control slides with a discrepancy only visible in the final 
incubation period, however despite this the end points remained rather similar (Original Magnification 
20X).   
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a.) HT29 CD133+ cells, no treatment control  
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b.) HT29 CD133+ cells, treated with tomatidine 
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Figure 46: Following the same trend as the DLD1 cell line, the HT29 CSC’s steady gap closure was 
visible in a.) the control and b.) cells incubated with tomatidine. While complete closure of the gap 
did not occur, many cells did however protrude into original cell free zone. c.) Despite the differing 
starting points the pattern seen by the control and tomatidine treated cells remains the same. Although 
a slight lag is observed in the 2 to 6 hour period there was a lack of overall impedance to migration. 
d.) The differences in scratch widths remain indistinguishable up until the last measurement where the 
control appeared to undergo a growth spurt resulting in the final scratch width being approximately 
the same regardless of the varying start widths (Original Magnification 20X).  
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The scratch/migration assays provided information on the ability of CD133+ CSC’s to 
migrate and close a gap in order to form a confluent cell monolayer once again (Figure 40-
46). Initial testing with drug was performed (see Appendix C) in order to determine an ideal 
scratch width, the most suitable duration for the assay as well as appropriate times of 
measurement. A 200µl micropipette tip was finally selected to create a narrow scratch, with 
the collection of more measurements in the first 6 hours of incubation so as to optimize the 
experiment for more precise measurement of gap closure rate.  The difference in scratch 
width gives an indication of the extent of the effect the small molecule inhibitors had on the 
CSC’s at the different time intervals. By assessing the differences in the progression of cell 
migration it can be seen that the most crucial time for drug activity is the first 6 hours of 
incubation.  DLD1 cells expressing CD133 showed steady cell growth and gap closure over 
the 6 hour period and almost complete closure after 24 hours. With the addition of 
cyclopamine a hindrance in gap closure is noticed within the first 6 hours thereafter normal 
growth is seen and the width is similar to that of the control after 24 hours of incubation. 
HT29 CSC’s responded similarly to cyclopamine as the DLD1 cell line suggesting that the 
drug has a negative effect on the ability to migrate within the first 6 hours. The effect of the 
small molecule inhibitor is visible graphically (see Figure 40-41) where the scratch actually 
increased in width before closing at the 6 hour mark, in contrast to the sustanined growth of 
the control throughout the 24 hour incubation period. DLD1 and HT29 CSC’s displayed a 
somewhat different response to SANT-2 treatment; despite both scratch widths beginning at 
approximately the same point, their end width differs significantly particularly in the DLD1 
cell line. This would infer that SANT-2 has an inhibitory effect on cell migration over the 24 
hour incubation period. This is in contrast to cyclopaminie that was effective only up to 6 
hours of treatment. Similar to the untreated control, tomatidine did not have any effect on cell 
migration, and the gaps being almost totally closed in both cell lines after 24 hours.  
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6.8 EXPRESSION OF SHH 
DLD1 CD133+  
      Untreated                    Treated with 2µM cyclopamine  
 
 
 
 
 
 
 
Figure 47: Expression of Shh in DLD1 CD133+ cells after treatment with cyclopamine, nuclei shown 
with (n) and apoptosis (A). Following incubation with 2µΜ cyclopamine it was found that the 
expression levels of cell surface Shh (red) had decreased indicated with arrows. This was visible by 
fluorescence microscopy after staining with a Shh specific primary antibody. The nuclei were stained 
with DAPI (blue) and F-actin filaments were stained with Phalloidin 488 (green). The relative CTCF 
values were calculated and displayed below (Original Magnification 63X).  
 
Table 25: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells, stained with an 
anti-Shh antibody prior to treatment and following with treatment with 2µM cyclopamine 
 
 
 
 
 
Untreated Integrated density Area of selected cell Background fluorescence CTCF 
 73039 1401 0.061 72953.53 
 72065 1805 0.061 71954.90 
 79110 1979 0.061 78989.28 
Average CTCF    74632.57 
Treated     
 39111 1036 0.987 38088.46 
 47091 1402 0.987 45797.23 
 51675 1352 0.987 50340.58 
Average CTCF    44742.09 
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HT29 CD133+  
     Untreated                    Treated with 2µM cyclopamine                                                          
 
 
 
 
 
 
 
 
Figure 48: Expression of Shh in HT29 CD133+ cells after treatment with cyclopamine, nuclei shown 
with (n) and apoptosis (A).Cell surface Shh (red) had decreased, indicated with arrows, following 
treatment with cyclopamine.Some Shh is still expressed following treatment but to a lesser extent. 
The nuclei were stained with DAPI (blue) and F-actin filaments were stained with Phalloidin 488 
(green) (Original Magnification 63X).  
 
Table 26: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells, stained with an 
anti-Shh antibody prior to treatment and following with treatment with 2µM cyclopamine 
 
 
 
 
Untreated Integrated density Area of selected cell Background fluorescence CTCF 
 135558 4530 0.008 135521.76 
 133743 4654 0.008 133705.77 
 142291 5097 0.008 142250.22 
Average CTCF    137159.25 
Treated     
 90720 2410 0.070 90551.3 
 88588 2102 0.070 88440.86 
 93988 2304 0.070 93826.72 
Average CTCF    90939.62 
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Figure 49: Shh expression in DLD1+ and HT29+ cells treated with cyclopamine. Both cell lines 
showed a decreased expression of Shh on their cell surface following treatment with the antagonist of 
the Hh signalling pathway.  
 
Following treatment with 2µM cyclopamine both DLD1 and HT29 CD133+ cells showed a 
decreased expression of Shh with significant decreases of 29890.48 units (** p= 0.0021) and 
46219.63 units (*** p= 0.0001) respectively (Figure 47-49). These decreases are visually 
apparent with the fluorescence intensity appearing far less intense after treatment with the 
drug.  
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6.9 EXPRESSION OF CD133 AND SHH 
DLD1 CD133+  
  Untreated                    Treated with 2µM cyclopamine 
 
 
 
 
 
 
 
Figure 50: The expression levels of CD133 in conjunction with Shh expression was assessed 
subsequent to treatment with cyclopamine (2μM). Nuclei were stained with DAPI (blue), Shh (green), 
and CD133 (red). A decrease in Shh can be seen with a minimal change in cell surface CD133 
expression (Original Magnification 63X). 
 
Table 27: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells, stained with an 
anti-Shh antibody prior to treatment and following treatment with 2µM cyclopamine 
 
Table 28: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells, stained with an 
anti-CD133 antibody prior to treatment and following treatment with 2µM cyclopamine 
Untreated Integrated density Area of selected cell Background fluorescence CTCF 
 53560 1542 1.092 51876.14 
 55875 2286 1.092 53378.69 
 46770 2054 1.092 44527.03 
Average CTCF    49927.29 
Treated      
 34510 1915 1.176 32257.96 
 37784 2513 1.176 34828.71 
 30516 2240 1.176 27881.76 
Average CTCF    31656.14 
Untreated Integrated density Area of selected cell Background fluorescence CTCF 
 20792 1800 3.896 13779.2 
 22186 1999 3.896 14397.9 
 23303 1774 3.896 16391.5 
Average CTCF    14856.2 
 
Treated       
 20949 2280 2.481 15292.32 
 20405 1952 2.481 15562.09 
 19377 1626 2.481 15342.89 
Average CTCF    15399.1 
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HT29 CD133+  
   
Untreated                    Treated with 2µM cyclopamine  
 
 
 
 
 
 
 
Figure 51:  Expression of CD133 in conjunction with Shh following treatment with cyclopamine 
(2μM). Nuclei were stained with DAPI (blue), Shh (green), and CD133 (red). A decrease in Shh is 
clearly evident; however a change in cell surface CD133 expression is not apparent (Original 
Magnification 63X). 
Table 29: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells, stained with an 
anti-Shh antibody prior to treatment and following treatment with 2µM cyclopamine 
Untreated Integrated density Area of selected cell Background fluorescence CTCF 
 201572 11079 4.894 147351.4 
 213184 12262 4.894 153173.8 
 201681 11257 4.894 146589.2 
Average CTCF    149038.1 
Treated     
 32548 2915 1.376 28536.96 
 34954 4331 1.376 28994.54 
 33584 2360 1.376 30336.64 
Average CTCF    29289.38 
 
Table 30: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells, stained with an 
anti-CD133 antibody prior to treatment and following with treatment with 2µM cyclopamine 
Untreated Integrated density Area of selected cell Background fluorescence CTCF 
 73640 5569 1.810 63560.11 
 71865 5396 1.810 62098.24 
 70347 5124 1.810 61072.56 
Average CTCF    62243.64 
Treated      
 74283 7849 0.978 66606.68 
 76223 7447 0.978 68939.83 
 75456 6697 0.978 68906.33 
Average CTCF    68150.95 
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Figure 52: Expression of Shh as well as CD133 in DLD1+ and HT29+ cells after treatment with 
cyclopamine. Both DLD1 and HT29 cells had a decreased expression of Shh following treatment with 
cyclopamine, however with no significant change in CD133 expression.  
 
In both the DLD1 (** p =0.0058) and HT29 (*** p=0.0001) CD133+ cells there was a 
significantly decreased expression of Shh following treatment with cyclopamine, with 
differences in the CTCF values of  18271.15 and 119748.72 respectively (Figure 50-52). A 
far greater decrease in expression was seen in the HT29 cell line. The expression of CD133 
did not decrease in either the DLD1 or HT29 cell lines.   
 
 
 
 
 
*** ** 
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6.10 CORRELATION OF METASTATIC PROPERTIES 
Correlation between decrease in adhesion and decrease in invasion with application of 
small molecule inhibitors: 
A distinct property of metastatic cells is the efficiency of their adhesive interactions with 
other cells as well as components of the extracellular matrix100.  Adhesion is a necessary step 
in the process of invasion and migration. Studies have shown that together, the adhesive and 
invasive potential of cancer cells have a high correlation (r=0.77)98, inferring that a reduced 
ability to adhere should result in a decreased invasive potential and migratory ability. In this 
study, with the application of small molecule inhibitors of the Shh pathway impeding cell 
adhesion, invasion, and migration this theory was tested. The linear dependence between two 
variables was expressed using Pearson’s (r) correlation coefficient. By using the difference in 
adhesion potential and the difference in invasion potential the following was calculated: 
Cyclopamine   SANT-2  Tomatidine 
r = 0.4299   r = 0.924  r = 0.2823 
By calculating the Pearson’s correlation co-efficient between the decrease in adhesion 
potential and the difference in invasion potential, it was found to be 0.4299, 0.924 and 0.2823 
for cyclopamine, SANT-2 and tomatidine respectively. This indicates that the correlation is 
positive for all three compounds, indicating a positive association with treatment. The 
strongest positive relationship is reflected following SANT-2 treatment and the weakest is 
with the cyclopamine analogue, tomatidine. Therefore, we propose that in most instances a 
decreased adhesion potential correlates with a decreased invasive potential.   
Correlation between decrease in adhesion and decrease in migration with application of 
small molecule inhibitors: 
Cyclopamine   SANT-2  Tomatidine 
r = -0.4287  r = 0.5021 r = -0.0352 
These results indicate that a decreased adhesion potential due to the action of SANT-2 results 
in a decreased ability to migrate. However, a decreased adhesive potential due to application 
of cyclopamine does not necessarily result in a decreased ability to migrate. The negative 
value calculated implies that there is a negative correlation, meaning that adhesion may 
decrease while migration may increase.  Similarly, this is the case with tomatidine, but there 
is only a slightly negative correlation in comparison to the strongly negative value of -0.4287 
calculated for cyclopamine.  
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7. DISCUSSION 
7.1 INTRODUCTION 
Evidence for the existence of Cancer Stem Cells (CSC’s) in solid tumours has accumulated in 
recent years20,22. It is believed that tumours are heterogeneous and upon dissociation and 
transplantation into an immune-compromised mouse model, human CSC’s are able to 
reinitiate and form a similar heterogeneous tumour in vivo.  While these cells display many 
characteristic features of mesenchymal stem cells in terms of their growth properties, they 
have however, also been found to be resilient to therapy101, are extremely invasive and 
therefore highly metastatic. CSC’s have been positively identified in, and isolated from 
various human solid cancers, including colon cancer27,28. Most colon cancers begin as local 
adenomas in the intestine and progress to invasive carcinomas. It has been suggested their 
recurrence and metastatic potential have been attributed to the presence of CSC’s expressing 
cell surface CD133102.  In the present study this cell surface protein has been used as a marker 
to successfully isolate and identify CSC’s from a heterogeneous cancer cell population. An 
active Hedgehog-Gli pathway has been detected in both human colon carcinoma cells and in 
their stem cells76. During embryonic development this pathway is a key regulator and ensures 
that axis symmetry as well as the correct distribution of cell types is maintained56. In adult 
tissue although the Hh pathway is mainly inactive57, it  is thought to play a role in regulating 
adult stem cells which consequently maintain and regenerate old or damaged tissue; and 
notably expression also occurs in human adult gut epithelium58. Reactivation of the Hh 
pathway in adult tissues may be linked to the development of some cancers which occurs 
either by the genetic modification of the pathway components or excessive secretion of the 
Hh ligands. The mechanism by which the Shh pathway is reactivated involves the surface 
protein Ptch suppressing the activity of the cytoplasmic protein Smo, however, following the 
binding of the Hh ligand to Ptch, this suppression is then inhibited. This then allows for the 
activation of downstream targets through the Gli transcription factors (Figure 53). When a Hh 
ligand is absent it results in the phosphorylation and cleavage of Gli.  However in the 
presence of a Hh ligand, Gli is not cleaved and the full length Gli translocates to the nucleus 
where it exhibits transcriptional activity and the up-regulation of key oncogenes. The 
involvement of this pathway specifically in metastasis by inducing Epithelial to 
Mesenchymal Transitions (EMT) makes it an obvious option for a targeted therapeutic. As 
mentioned, Sonic Hedgehog (Shh) inhibitors such as cyclopamine have been successful in the 
treatment of other cancer types including basal cell carcinoma, medulloblastoma and 
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rhabdomyosarcoma59. The pathway inhibition induced by this small molecule is as an 
antagonist of Smo preventing activation of Gli, its movement into the nucleus and thus 
precluding oncogene transcriptions. 
 
Considering the need for targeted therapy against cancer stem cells and their occurrence in 
colon cancer, as well as the role of Shh in EMT and metastasis, we hypothesized that 
disrupting this pathway using small molecule inhibitors would be effective in impeding the 
invasive and adhesive potential of colorectal CSC’s.  
 
7.2 ISOLATION OF CSC’S 
 
In this study CSC’s were successfully isolated from 3 colorectal cancer cell lines representing 
early and middle-late stages of the disease. The SW480 cell line which is thought to be 
derived from an early tumour was found to contain very few CSC’s upon several attempts at 
separation. These cells proved to be too few in number to proliferate and form a new 
population of stem cells in the specified media. It is for this reason that confirmation by flow 
cytometry was not possible and therefore these cells were not used in experiments thereafter. 
The low number of stem cells in early tumours concurs with the literature wherein more 
advanced (metastatic) cancers have been found to contain far higher quantities of stem cells 
in comparison to early stage tumours. In a cohort study fewer Dukes’ stage A tumours (5%) 
were found to have expression of CD133 in comparison to Dukes’ stage B and C tumours 
(25%)103.  With the DLD1 and HT29 cell lines which are representative of middle-late stage 
colon cancer, sufficient quantities of stem cells were isolated and this allowed for the 
culturing of a relatively pure stem cell population of each line. The increased number of 
CD133+ cells found in cancer cell lines most likely results from their oncogenic 
transformation104.  
 
Following the magnetic separation the stem cells were cultured in a defined media lacking 
FBS to maintain the cells in an undifferentiated state. The media did however contain several 
other defined growth factors that promoted cell proliferation, including insulin, FGF and 
EGF. The isolated cells initially grew typically as spheroids and thereafter were able to 
adhere to the cell culture plate to form a single monolayer. The ability to form spheroids is a 
distinct characteristic of CSC and studies have shown that primary cancer cells from adherent 
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cultures fail to form these structures when grown in a 3D culture system105. Other studies 
using colon cancer cells report that about 1 in 16 CD133 expressing cells have an increased 
ability to form spheroids, whereas approximately only 1 in 250 CD133- cells have this same 
ability, inferring that it is more likely that spheroid formation will occur in a cell population 
that express cell surface CD133102. 
 
After several days of growth the isolated cells reached a sufficient level of confluence for 
flow cytometry analysis. Using the CD133 receptor as a definitive marker the DLD1 CSC’s 
had a purity level of 73%; and similarly, the HT29 cell line displayed a 70% purity level. 
This level of purity is above what was found in literature where after magnetic separation of 
glioblastoma-derived CSC’s a purity level of 53% was determined using flow cytometry106. 
 
7.3 CSC GROWTH PROFILES  
 
As mentioned previously, the isolated CSC’s initially grew as typical spheroids, a property 
indicative of “stemness”. Next, their expression of CD133 was then confirmed by flow 
cytometry, and taken together, it could therefore be deduced that a CSC population had been 
isolated from a general non-CSC population and a comparison could be then made in terms 
of their proliferation rate and growth patterns. The use of a real-time cell analyser was 
employed to carefully elucidate the differences in the growth patterns between “normal” 
colon cancer cells and colon CSC’s. As little is known about the behavior of colon CSC’s, 
this assay provided some insights into the proliferation patterns of these cells.  
 
Prior to determining a characteristic real-time growth curve, the optimal seeding density of 
each cell type was determined in a titration assay. This is important since an excess of cells 
will result in rapid overgrowth, whilst a nominal cell number may negatively affect cell 
growth. From the preliminary study, the optimal number of cells needed to form a suitable 
growth curve was found to be 50 000 cells/ml for the CSC’s and 25 000 cells/ml for the non-
CSC’s. These concentrations were then employed in subsequent experiments.  
 
Following the determination of optimal cell seeding densities, real time cell impedance 
assays were carried out. The real-time proliferation curves generated showed distinct 
differences between DLD1 and HT29 cell lines. This was somewhat expected as all cell lines 
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have a distinct signature pattern and deviations from this would indicate stimulation, 
suppressed growth or even apoptosis. Notably, we report here a defined difference in the 
growth pattern of the CSC’s (CD133+) as compared to their non-CSC (CD133-) counterparts. 
The non-CSC’s grew more rapidly, reaching confluence in approximately 48 hours, while the 
CSC’s required at least 72 hours. This differing growth pattern was reflected in the cells 
derived from both cell lines. These results are in accordance with the literature, where it is 
reported that stem cells generally have a slower proliferation rate in comparison to normal 
cells99.  
 
The cancer stem cell model suggests that these cells display similar characteristic features to 
normal stem cells, including entering the cell cycle infrequently. This is one of the biggest 
challenges therapeutically, since current therapies are designed to abolish rapidly cycling 
cells, rather than slow cycling CSC’s, making the CSC’s highly resistant107.  The proliferation 
assay clearly displayed the slow cycling of CSC’s expressing CD133 in comparison to non-
CSC’s.  
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7.4 STEM CELL MARKER EXPRESSION  
After observing the morphological and proliferation properties of the isolated CSC’s the 
expression of a number of key stem cell markers were evaluated in the CSC’s and non-
CSC’s, using confocal microscopy. Apart from CD133, these included c-Myc, KLF4 and 
alkaline phosphatase, and their relevance is discussed below.  
 
7.4.1 CD133  
This marker was assessed both on the cell surface and cytoplasmically. Firstly CD133 was 
detected in non-permeabilised cells on the cell surface and subsequently within the cytoplasm 
of detergent permeabilised cells. In all instances, the CD133+ cells expressed more cell 
surface and cytoplasmic CD133 than the CD133- cells. From this analysis, it would seem that 
the CSC’s express CD133 on their cell surface, whilst non-CSC’s only express it 
intracellularly.  
 
The CD133+ and CD133- permeabilized cells of both cell lines displayed cytoplasmic 
expression of CD133. Since CD133 is a secreted protein, following translation it would be 
processed through the endoplasmic reticulum, where it would probably undergo 
glycosylation, a step required for protein secretion onto the cell surface. The observed 
perinuclear association of CD133 may reflect its association with the trans-Golgi network, 
which is closely associated with the nucleus. Furthermore, the lack of cell surface CD133 in 
CD133- cells (non-permeabilized) from both cell lines may relate to a functional absence of 
secreted CD133.  
 
To better elucidate the cellular localization of CD133, Z-stack analyses were performed to 
reflect CD133 expression in relation to the nuclei and cell membrane. These confirmed the 
confocal observations of cell surface CD133 on non-permeabilized CD133+ DLD1 and HT29 
cells. Moreover, the nuclear association of CD133 was corroborated in permeabilized cells by 
co-localization of DAPI and Alexa Fluor 532 staining, producing a pink coloration.  
 
It should however be noted here that some of the cells, (approximately 10%) in the negative 
fraction did express CD133. This may relate to the negative fraction being a heterogenous 
population of cells, containing a few cells that were able to dedifferentiate into CSC’s. It is 
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also possible that the magnetic separation may not have been absolutely effective, allowing a 
few positive cells to be washed into the negative fraction.  
 
The purity of the cell sample in the present study could have possibly been improved by 
performing an additional separation or passing it through the isolation column several more 
times. Such an approach has proven effective in other studies where CD133 was also used as 
a CSC marker. It was found that the CSC’s accounted for a mere 2.5% of the original 
population by expressing the marker CD133 and these CSC’s were isolated as  using the 
same magnetic separation kit employed in this study28.  
 
 
From these results it can clearly be seen that a successful magnetic separation took place 
since selection was made based on the CD133 receptor.  These microscopy images were 
captured after several weeks of growth in the selective CSC media. From this one can deduce 
that the cell surface expressed CD133 would be a fair indication of stemness of cancer cells. 
 
7.4.2 c-Myc 
The regulator gene c-Myc codes for a transcription factor that plays a key role in cell cycle 
progression, regulation of cell growth, differentiation and apoptosis48. Mutations in the gene 
may arise and in many cases results in the formation of cancer. The two cell lines chosen for 
this study, DLD1 and HT29, both express the myc oncogene (see Appendix A). Not only is 
this gene activated upon mitotic signals such as Shh, it is also a factor implicated in the 
production of human induced pluripotent stem cells108. c-Myc was selected in this study as a 
stem cell marker and its expression was evaluated using fluorescent microscopy.  
 
7.4.3 KLF4 
This marker which forms part of the KLF family of transcription factors plays a role in 
regulating various cellular processes including differentiation, proliferation and apoptosis. 
Furthermore it has been found to be a tumour suppressor in colorectal cancer109.   Expression 
of this gene has also proven to be an accurate indicator of “stemness” in embryonic and 
mesenchymal stem cells50. Its capacity as being a factor for the generation of human induced 
pluripotent stem cells has also been demonstrated. It forms part of the group of genes which 
includes Oct3/4, SOX2, c-Myc, nanog, LIN28 and Glis1 all of which have been identified as 
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crucial transcriptional regulators involved in the induction process of human pluripotent stem 
cells50. For these reasons it was selected as a marker in this study to further characterize the 
isolated CSC’s. 
 
This was done by observing the levels of c-Myc and KLF4 expressed on the cell surface of 
CD133+ cells. It was found that the level of both markers was increased, (not significantly 
for c-Myc levels in DLD1 cells) in DLD1 and HT29 CD133+ cell lines in comparison to the 
CD133- counterparts. Selected CD133+ cells expressed c-Myc strongly but overall the 
expression of c-Myc was elevated in both the CD133+ fractions of the DLD1 and HT29 cell 
lines. This was to be expected since both markers are indicators for the presence of CSC’s. 
 
7.4.4 Alkaline phosphatase 
Alkaline phosphatase has long been known as a stem cell marker whereby its presence in 
high levels provides an indication of pluripotency51. In humans four isoenzymes have been 
identified namely; intestinal alkaline phosphatase, placental alkaline phosphatase, germ cell 
alkaline phosphatase (expressed in primordial cells), and tissue non-specific alkaline 
phosphatase. Intestinal, placental and germ cell alkaline phosphatase are expressed by 
embryonic cells as well as carcinoma cells110.  
 
Like CD133 alkaline phosphatase is membrane bound and can therefore be identified on the 
cell surface of potential CSC’s, however in some instances the enzyme is also secreted 
extracellularly. Of all the stem cell markers evaluated in this study, the most distinct 
difference was observed in alkaline phosphatase levels. The high expression of alkaline 
phosphatase in the CD133+ fractions of DLD1 and HT29 cells was found to be significantly 
higher in comparison to the CD133- fractions and further confirms the “stemness” of the 
CD133+ cells. Moreover, the expression of alkaline phosphatase indicates that the cells are 
pluripotent and undifferentiated. Overall, the over-expression of CD133 and other stem cell 
markers was visually apparent in the stem cell fractions of both cell lines, providing 
convincing evidence of the existence of a stem cell population. A definite isolation of CSC’s 
had to be made in order to continue with further experiments in this study as a mixed 
population would not provide accurate results nor insight into the effects of CSC-targeted 
drugs. 
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7.5 THERAPEUTIC DEVELOPMENT  
 
With the recent discovery and development of the cancer stem cell theory, researching 
possible therapeutics aimed at blocking the activation of this pathway could prove to be most 
valuable since CSC’s seemingly display the same properties as their normal human stem cell 
counterparts and are regulated by the same signalling molecules95. Inhibiting the Shh 
pathway would result in minimal side effects due to its limited activation in adults. 
Furthermore a targeted therapeutic would avoid collateral damage to other normal tissue. 
Various drugs have been developed and affect different components of the Shh pathway 
including the Hh ligand itself, the surface proteins Ptch and Smo, as well as the Gli 
transcription factors.  
The target of the compound cyclopamine is Smo and the semi-synthetic derivative of it 
Saridegib (IPI-926), is currently available for the treatment of haematologic malignancies. 
Cyclopamine is appealing as a cancer therapeutic since it is a natural compound and rather 
well established, however, synthesis of it in large enough quantities has proven to be 
challenging. A further drawback is its relatively low affinity for Smo111,112. Although 
Saridegib has an extended half-life, it is only effective in the treatment of a subset of Hh 
dependent tumours. A Phase II trial using Saridegib in conjunction with gemcitabine for the 
treatment of pancreatic cancer was recently stopped due to the drug showing limited 
efficacy113.  Other analogues of cyclopamine including KAAD-Cyclopamine and HhAntag-
691 have shown an increased efficiency in comparison to cyclopamine but are still under 
investigation and have not been proven safe for clinical trials yet 59,114. In order for 
cyclopamine and these other analogues that target Smo to be effective in the treatment of 
cancer certain criteria must be met. In particular, the cancer type must be dependent on the 
activation of the Hh ligand or induced by mutations in the receptors Ptch and Smo. Once the 
aforementioned criteria have been met, it is essential to develop a mechanistic understanding 
of Smo and its interaction with these compounds. This research made use of Smo inhibitors 
in the form of the small molecules cyclopamine and the analogue SANT-2 which are believed 
to be potent antagonists of the Hh pathway. 
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7.6 ASSESSMENT OF PHYSIOLOGICAL PROPERTIES OF CSC’S 
 
As mentioned previously, cancer cells display distinct characteristics in comparison to normal 
cells which allow them to thrive and grow uncontrollably (Figure 53). A key hallmark, which 
is a particular focus of this study, is the ability to invade surrounding tissue and metastasize. 
The ability of tumorigenic cells to travel to distant sites and form secondary tumours are the 
cause of 90% of cancer-related deaths in humans115.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53: Aquired capabilities of cancer; developed through mutations, activation of oncogenes or 
silencing tumour suppressor genes (adapted from Figure 196).  
 
It is believed that CSC’s have an enhanced ability to invade surrounding tissue and are highly 
metastatic116. Furthermore cells isolated from an invasive pancreatic tumour were found to 
express CD133, classified as CSC’s, and determined the metastatic phenotype of the 
individual tumour104. In this study CSC’s isolated from the two colorectal cancer cell lines 
DLD1 and HT29 were subjected to various assays analysing their ability to adhere (a vital 
step in metastasis, see Figure 54), to invade, and migrate in vitro and key findings are 
described below.    
CANCER 
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7.6.1 Cell adhesion  
 
Figure 54: Schematic diagram illustrating initial cell adhesion, invasion, and Type IV-collagenase 
ECM degradation allowing for cell migration.  1.) Attachment of CD133 expressing tumorigenic cell 
to Laminin-1 on the basement membrane. 2.) Digestion of the basal lamina by Type IV-collagenase 
secretion induced upon attachment, 3.) Degradation of the basement membrane allows for 
tumorigenic cell motility into the blood stream (modified from graphical abstract, A. Omar, et al 
201298). 
 
The positively identified isolated CSC’s were subjected to various forms of testing with the 
inclusion of the small molecule inhibitors. Their ability to adhere to Geltrex™ (components 
of a Laminin ECM) was evaluated as this was an important step towards the elucidation of 
CSC behaviour and their capacity to metastasize. Observing the effects that cyclopamine 
would have on the adhesive and invasive potential of CSC’s was vital since the Shh pathway 
has been found to play a major role in metastasis. The first parameter to be assessed was cell 
adhesion to a laminin based extracellular matrix. The activation of the cell adhesion pathway 
is an important step in the mesenchymal transition, as well as in the upregulation of 
metastasis-associated genes such as SNAIL95.  By quantifying the ability of CSC to adhere 
with the use of an adhesion assay, and juxtaposing these results with those of  non-CSC’s it 
was possible to see that although non-CSC are capable of successfully adhering to a 
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Geltrex™ coated surface, CSC’s are even more proficient at this supporting notion that  
CSC’s  have an enhanced adhesion potential117. A significantly increased adhesion potential 
was noted in the CD133+ fractions of both the HT29 and DLD1 cell lines in comparison to 
their negative fractions. This reveals that the CSC’s have an enhanced ability to adhere, a key 
step in the process of metastasis. Small molecule inhibitors were employed to assess the role 
of the Shh pathway in the adhesive ability displayed by the CSC’s. Upon the application of 
2μM cyclopamine a marked reduction in the adhesion potential was observed in both HT29 
CSC’s and DLD1 CSC’s in comparison to untreated cells. These results are in agreement 
with previous studies performed within the Oncology Laboratory and unpublished data 
indicated that at a concentration 2µM metastatic behaviour was inhibited and concentrations 
above this induced apoptosis. The effect noted, that is blockage of the Shh pathway, with this 
concentration of cyclopamine is expected and has been observed in in vivo studies using 
mice118. When SANT-2 was applied at this same concentration no reduction in adhesion 
potential was found. Subsequently, when a dose dependency assay was performed, SANT-2 
was found to be effective only in impeding adhesion at a concentration of 10µM or higher. It 
appears that cyclopamine had a greater inhibitory effect on the DLD1 cell line while SANT-2 
was more effective in hindering adhesion in the HT29 cell line. The reason for this while 
unknown, it was however noted that slightly elevated levels of CD133 were detected in the 
DLD1 cell line in comparison to HT29 cells and this could possibly be related. This would 
suggest that therapeutics targeting CD133 would be highly effective in the treatment of 
CSC’s. The cyclopamine analogue tomatidine had no effect in adhesion assays.  
 
7.6.2 Cell invasion 
In order to further understand the effect cyclopamine and the other small molecules would 
have on the process of metastasis, in vitro invasion assays were performed. Following 
adhesion to cell membranes in vivo, neoplastic cells require the ability to invade surrounding 
tissue or enter the blood or lymphatic system. Once attached to a target basement membrane, 
this is enzymatically digested by Type IV-collagenase, allowing entry into the circulatory 
system, migration and finally a metastatic (secondary) tumour is then established by 
attachment of migrating cells to the blood vessel once again119. Therefore, as invasion assays 
mimic this process, they provide an indication of the ability of cells to pass through an 
extracellular matrix (Laminin-1) coated membrane similar, to that of the basal lamina. CSC’s 
from both the DLD1 and HT29 cell lines migrated through the matrix coated membrane 
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attaching to the underside. However, the inclusion of cyclopamine (2μM) or SANT-2 in the 
assay, significantly hindered cell invasion resulting in far fewer numbers of cells traversing 
through the membrane. SANT-2 (20μM) treatment effected the most significant reduction in 
invasive potential in the HT29 derived stem cells. The cyclopamine (control) analogue, 
tomatidine, as expected had no significant effect on cell invasion. These findings concur with 
the adhesion assays, since cell adhesion is a pre-requisite step for invasion to occur. In this 
regard, a positive correlation between adhesion and invasion has been reported in previous 
studies using breast, lung, cervix, prostate and colon cancer cell lines98. Moreover, on further 
analysis, we report here a positive correlation between the effects of cyclopamine and SANT-
2 on limiting both cell adhesion and invasion (note a positive Pearson’s correlation co-
efficient of 0.43 and 0.924 was calculated for cyclopamine and SANT-2 respectively, see 
results section 6.10). It follows that in most instances a decreased ability of cells to adhere to 
matrix molecules correlates with a diminished invasive potential. This would have 
implications in therapeutic efficacy since drugs targeting the adhesion of neoplastic cells 
could result in them having a decreased ability to invade surrounding tissue and migrate.  
 
7.6.3 Cell migration 
As mentioned, following attachment and invasion across the basement membrane neoplastic 
cells then need to invade surrounding tissue, adhere again, and proliferate to form a 
secondary tumour. This process involves the ability of cells to migrate and undergo EMT. For 
successful motility to occur cellular signalling networks are activated and in turn induce 
morphological changes120, whereby cells lose their epithelial characteristics and assume 
mesenchymal-like features such as their expression of E-cadherin. These signalling networks 
encompass various molecules and receptors that may respond to stimuli, or may be affected 
by inhibitors; and can be assessed in vitro using cell migration or scratch assays120. In a study 
using colorectal CSC’s it was found that the biomarker CD44v6 was over-expressed and 
played a pivotal role in migration and the formation of metastatic tumours. The expression of 
CD44v6 was stimulated by cytokines and thereby the Wnt/β-catenin pathway was activated. 
Furthermore, inhibition of this expression resulted in a decreased migration and metastatic 
growth, and CD44v6 was shown to be both a functional biomarker as well as therapeutic 
target121. 
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In assessing the inhibition of the Hedgehog pathway in the present study, cyclopamine 
effected a limited inhibition of cell migration inclusive of up to 6 hours in both DLD1 and 
HT29 cells, after which migration appeared to reflect that of the controls. Interestingly, the 
cyclopamine caused an initial widening of the gap (in the first 4 hours), perhaps caused by 
the induction of apoptosis. This finding concurs with studies done using cyclopamine 
whereby cell proliferation was arrested and possibly apoptosis induced73,81. In contrast, 
SANT- 2 was highly effective in retarding cell migration over the full 24 hour period of 
treatment.  
From these results one can deduce that both cyclopamine and SANT-2 were able to disrupt 
pathways involved in the migration of colon CSC’s and their ability to populate a cell free 
zone, however the negative effect of cyclopamine appeared to be neutralized after 6 hours 
perhaps due to a shorter half-life (cyclopamine half-life 1.1 +/- 0.1 h). Another possibility 
could be that the drug becomes ineffective as Smo may undergo mutations that allow for the 
activation of the Shh pathway by acquired resistance (Figure 55). There are reports of 
mutations occurring in Smo, rendering Smo inhibition ineffective. In this regard, Smo 
mutation has been noted with use of the Smo inhibitor GDC-0449 whereby initial tumour 
regression was seen in the patient, followed by recurrence of metastatic tumours due to 
mutations in Smo resulting in drug resistance122. Pathway-specific resistance that may 
develop during Smo antagonist treatment could occur at the site of Smo, whereby the drug is 
unable to interact with Smo and therefore Hh activation results in tumour progression123. The 
potential of Hh pathway inhibitors is evident in this same study as the patients’ tumours were 
unresponsive to conventional therapeutic agents124. Other studies have shown that 
cyclopamine acts to stimulate an accumulation of Smo within the cell’s primary cilium and 
upon drug removal, continuous activation of the pathway could result93. This could explain 
the lack of inhibitory effect of cyclopamine reported here, following 6 hours of treatment in 
the migration/scratch assay.   
A correlation between a hindered adhesion of CD133+ CSC’s and a decreased migration was 
calculated as being -0.429 and 0.502 for cyclopamine and SANT-2 respectively (see Results 
section 6.10). This would suggest that SANT-2 is effective in impeding cell adhesion and 
thereby a decreased migratory ability results; however with the application of cyclopamine it 
may decrease adhesion but not necessarily migration, hence the negative correlation. 
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Figure 55: Shh pathway inhibition and mutations. (A) Diagram illustrating an inactive Hh pathway 
whereby Ptch inhibits Smo. (B) The mechanism by which the Shh pathway is reactivated: following 
the binding of the Hh ligand to Ptch, this suppression is then inhibited allowing for the activation of 
downstream targets through the Gli transcription factors. (C) With the addition of the Smo antagonist 
cyclopamine Hh activation is suppressed and tumour progression is retarded. (D) Smo point mutations 
can occur and nullify the effect of Smo antagonists, Hh activation continues and tumour growth 
results due to the expression of Gli target genes (own figure).   
 
7.6.4 Inhibition of Shh; relationship to CD133 expression 
 
Finally the potential effect of Shh inhibition was queried in relation to the expression of the 
cancer stem cell marker CD133. This is of some importance with a view to targeting CSC’s. 
Notably here, with cyclopamine treatment, the cell surface expression of Shh significantly 
decreased in comparison to the untreated control. However, there was no apparent reduction 
in the expression of cell membrane associated CD133, suggesting that this particular stem 
cell marker is not necessarily influenced by the Hh pathway. From this, it would seem that 
cyclopamine possibly has no effect on the ability of CSC’s to express CD133.    
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7.7 FUTURE DIRECTIONS 
 
This research aimed at evaluating a targeted therapeutic against the Shh pathway in colorectal 
CSC’s. Although Shh inhibition had no direct effect on CD133 expression, the neoplastic 
properties of the CD133+ CSC’s were inhibited. This could suggest that another stem cell 
pathway or a related signalling pathway was affected by cyclopamine and SANT-2 treatment. 
Under normal circumstances this pathway is essential in embryonic development. After birth 
however the pathway remains active at sites of continuous renewal for example in the gut 
epithelium and when repair of tissue is required95.  An organ where this would be of concern 
would be the brain and since cyclopamine and other small molecules are able to cross the 
blood-brain barrier the consequences of the drug hampering the Shh pathway in neural tissue 
could be detrimental since regular stem cell renewal is vital. In studies where the growth of 
medullablastomas and gliomas was stunted in mice following treatment with cyclopamine, no 
notable side effects were documented; however minor cognitive defects could not be 
analyzed in mice114. The possibility that cyclopamine reduces the number of normal stem 
cells is rather likely and this side effect could become apparent when regeneration is required. 
However, localized and limited treatment with the drug could leave quiescent stem cells 
unaffected and allow for them to once more demonstrate their ability to self-renew and 
induce tissue regeneration. Other challenges with the application/use of the drug could 
include the increased intestinal epithelial proliferation that occurs in neonates and the 
possible side effect of tumour formation resulting from this125. This as well as the problems 
that could occur during injury, such as the inability to repair damaged tissue (particularly in 
the colon), are issues that must be given careful consideration and further experimentation is 
required in order to rule these out as harmful side effects.  
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7.8 OUTLOOK 
 
The therapeutic potential of cyclopamine and its analogues for the treatment of colon CSC’s 
is clearly evident but a better understanding of the genes expressed would certainly provide 
direction regarding drug limitations and how best to enhance the potential anti-metastatic 
effects. In this regard, it would be of particular interest to investigate the Shh pathway with 
respect to EMT, since as reported in the present study, properties of cell adhesion, migration 
and invasion were specifically implicated with the colon CSC population. A sensitive assay 
would be gene expression in an array format, to detect the up-regulation and down-regulation 
of pathway specific genes.  This would need to be done together with protein expression 
studies, since changes in mRNA transcript levels don’t necessarily equate to increased 
pathway activity. Together, these tools would permit for a finer evaluation of the small 
molecule inhibitors and their role/s in the Shh pathway. Recent studies have shown that 
cyclopamine successfully down-regulated the expression of pluripotent markers, EMT 
markers and Shh downstream markers in the colon cancer cell line HCT-116126. The Shh 
pathway could also be inhibited using anti-Hh antibodies which block the binding of the Hh 
ligand and therefore do not involve the impedance of Smo. Although a promising tool for the 
treatment of many cancer types, Smo antagonists are not always effective since the activation 
of the Hh pathway in certain cancers occurs downstream of Smo. The only way to 
successfully prevent disease progression in all Hh pathway dependent tumours would be to 
develop therapeutics that focus on the impairment of the downstream Gli transcription 
factors. Cases where pathway activation occurs downstream of Smo and cyclopamine would 
no longer be an effective therapeutic agent, other strategies such as SuFu mimetics and 
GliRNAi could be employed instead since their effects are downstream of Smo 95. These 
strategies would result in an antagonistic effect on the Hh pathway and block Gli 
translocation.  
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9. APPENDIX 
APPENDIX A 
Cell line data sheets: 
DLD-1 (ATCC® CCL-221™) 
Organism Homo sapiens, human 
Tissue Colon 
Cell Type Epithelial 
Morphology Epithelial 
Culture Properties Adherent 
Biosafety Level 1 
Disease Dukes' type C, colorectal adenocarcinoma 
Age Adult 
Gender Male 
Applications This cell line is a suitable transfection host. 
Derivation DLD-1 is one of two colorectal adenocarcinoma cell lines which were isolated by D.L. 
Dexter and associates during a period from 1977-1979 
Oncogene myc +; myb + ; ras +; fos +; sis +; p53 +; abl -; ros -; src - 
Genes Expressed carcinoembryonic antigen (CEA) 0.5 ng/106 cells/10 days; colon antigen 3. 
Cellular Products carcinoembryonic antigen (CEA) 0.5 ng/10 exp6 cells/10 days; colon antigen 3; keratin 
Tumorigenic Yes 
Effects Yes, in nude mice 
(Tumours developed within 21 days at 100% frequency (5/5) in nude mice inoculated 
subcutaneously with 10(7) cells) 
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HT29 (ATCC® HTB-38™) 
Organism Homo sapiens, human 
Tissue Colon 
Morphology Epithelial 
Culture Properties Adherent 
Biosafety Level 1 
Disease colorectal adenocarcinoma 
Age 44 years adult 
Gender Female 
Ethnicity Caucasian 
Applications This cell line is a suitable transfection host. 
Derivation The HT-29 line was isolated from a primary tumour in 1964 by J. Fogh using the 
explant culture method. 
Oncogene myc +; ras +; myb +; fos +; sis +; p53 +; abl -; ros -; src - 
Genes Expressed secretory component of IgA; carcinoembryonic antigen (CEA); transforming growth 
factor beta binding protein; mucin,myc +; ras +; myb +; fos +; sis +; p53 +; abl -; ros 
-; src -,Blood Type A; Rh+; HLA A1, A3, B12, B17, Cw5,HT-29 cells are negative 
for CD4, but there is cell surface expression of galactoseceramide (a possible 
alternative receptor for HIV). 
Cellular Products secretory component of IgA; carcinoembryonic antigen (CEA); transforming growth 
factor beta binding protein; mucin 
Tumorigenic Yes 
Effects Yes, in nude mice; forms well differentiated adenocarcinoma consistent with colonic 
primary (grade I); tumours also form in steroid treated hamsters 
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SW480 [SW-480] (ATCC® CCL-228™) 
Organism Homo sapiens, human 
Tissue Colon 
Morphology Epithelial 
Culture Properties Adherent 
Biosafety Level 1 
Disease Dukes' type B, colorectal adenocarcinoma 
Age 50 years 
Gender Male 
Ethnicity Caucasian 
Applications This cell line is a suitable transfection host. 
This line has a mutation in codon 12 of the ras proto-oncogene, and can be 
used as a positive control for PCR assays of mutation in this codon. 
Derivation SW480 was established from a primary adenocarcinoma of the colon. 
Oncogene myc +; myb + ; ras +; fos +; sis +; p53 +; abl -; ros -; src - 
Genes Expressed carcinoembryonic antigen (CEA) 0.7 ng/10 6 cells/10 days; keratin; 
transforming growth factor beta,myc +; myb + ; ras +; fos +; sis +; p53 +; abl -; 
ros -; src -,HLA A2, B8, B17; blood type A; Rh+,The cells are positive for 
keratin by immunoperoxidasestaining.,The line is positive for expression of c-
myc, K-ras, H-ras, N-ras, myb, sis and fos oncogenes. 
Cellular Products carcinoembryonic antigen (CEA) 0.7 ng/10 exp6 cells/10 days; keratin; 
transforming growth factor beta 
Tumorigenic Yes. Tumours developed within 21 days at 100% frequency (5/5) in nude mice 
inoculated subcutaneously with 10(7) cells. 
Effects Yes, in nude mice 
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Results: Microscopy controls  
Localization of CD133 expression in DLD1 and HT29 cells 
A.)  DLD1 CD133+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells (non-
permeabilized); negative control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1414 646 0.111 1342.294 
 1472 694 0.111 1394.966 
 1571 874 0.111 1473.986 
Average CTCF    1403.749 
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B.) HT29 CD133+ 
 
 
 
 
 
 
 
C.)HT29 CD133- 
 
 
 
 
 
 
 
Table B: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells (non-
permeabilized); negative control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1270 448 0.011 1265.072 
 1069 820 0.011 1059.98 
 1176 844 0.011 1166.716 
Average CTCF    1163.923 
 
Table C: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells (non-
permeabilized); negative control   
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 736 340 0.087 706.42 
 867 377 0.087 834.201 
 705 401 0.087 670.113 
Average CTCF    736.9113 
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D.) DLD1 CD133+  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E.) DLD1 CD133- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table D: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells 
(permeabilized); negative control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1837 565 0.161 1746.035 
 1799 1136 0.161 1616.104 
 1682 703 0.161 1568.817 
Average CTCF    1643.652 
 
Table E: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells 
(permeabilized); negative control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 658 559 0 658 
 641 533 0 641 
 613 810 0 613 
Average CTCF    637.3333 
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F.) HT29 CD133+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G.) HT29 CD133- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table F: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ (permeabilized); 
negative control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 519 171 0.033 513.357 
 544 334 0.033 532.978 
 608 325 0.033 597.275 
Average CTCF    547.87 
 
Table G: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- (permeabilized); 
negative control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 221 416 0.028 209.352 
 301 472 0.028 287.784 
 364 524 0.028 349.328 
Average CTCF     282.1547 
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Expression of c-Myc 
H.) DLD1 CD133+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.) DLD1 CD133- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table H: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 260 447 0.089 220.217 
 181 493 0.089 137.123 
 165 390 0.089 130.29 
Average CTCF    162.5433 
 
Table I: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 733 572 0 733 
 665 520 0 665 
 581 964 0 581 
Average CTCF    659.6667 
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J.) HT29 CD133+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
K.) HT29 CD133- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table J: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 402 421 0.168 331.272 
 496 703 0.168 377.896 
 455 338 0.168 398.216 
Average CTCF    369.128 
 
Table K: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 453 816 0.005 448.92 
 403 551 0.005 400.245 
 405 547 0.005 402.265 
Average CTCF    417.1433 
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Expression of KLF4 
 
L.) DLD1 CD133+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M.) DLD1 CD133-  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table L: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 661 618 0.027 644.314 
 506 530 0.027 491.69 
 523 589 0.027 507.097 
Average CTCF    547.7003 
 
Table M: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1597 517 0.519 1328.677 
 1649 545 0.519 1366.145 
 1666 679 0.519 1313.599 
Average CTCF    1336.14 
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N.) HT29 CD133+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O.) HT29 CD133- 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table N: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1395 779 0.149 1278.929 
 1481 547 0.149 1399.497 
 1371 612 0.149 1279.812 
Average CTCF    1319.413 
 
Table O: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 581 483 0.092 536.564 
 500 546 0.092 449.768 
 575 304 0.092 547.032 
Average CTCF    511.1213 
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Expression of alkaline phosphatase 
P.) DLD1 CD133+ 
 
 
 
 
 
 
 
Q.) DLD1 CD133- 
 
 
 
 
 
 
 
Table P: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133+ cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 1141 825 0.048 1101.4 
 1287 1100 0.048 1234.2 
 1268 1554 0.048 1193.408 
Average CTCF    1176.336 
 
Table Q: Corrected Total Cell Fluorescence (CTCF) of DLD1 CD133- cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 310 553 0.102 253.594 
 348 532 0.102 293.736 
 296 626 0.102 232.148 
Average CTCF    259.826 
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R.) HT29 CD133+ 
 
 
 
 
 
 
 
 
S.) HT29 CD133- 
 
 
 
 
 
 
 
Table R: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133+ cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 681 579 0.141 599.361 
 707 543 0.141 630.437 
 696 589 0.141 612.951 
Average CTCF    614.2497 
 
Table S: Corrected Total Cell Fluorescence (CTCF) of HT29 CD133- cells; negative 
control 
 Integrated 
density 
Area of 
selected cell 
Background 
fluorescence 
CTCF 
 166 817 0.14 51.62 
 175 443 0.14 112.98 
 146 393 0.14 90.98 
Average CTCF    85.19333 
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APPENDIX C 
Results: Scratch assay performed with cyclopamine treatment before optimization 
DLD1 CD133+ control 
 
 
 
 
0 hours         6 hours    24 hours 
DLD1 CD133+ with cyclopamine 
 
 
 
 
0 hours    6 hours                  24 hours  
HT29 CD133+ control 
 
 
 
 
 
0 hours         6 hours     24 hours  
HT29 CD133+ with cyclopamine 
 
 
 
 
0 hours      6 hours     24 hours 
Scratch assays practiced with implementation of cyclopamine in DLD1+ and HT29+ cell 
lines over 24 hour period with measurements taken at 0, 6 and 24 hours.  
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APPENDIX D 
Turnitin report:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
APPENDIX E 
Ethics waiver: 
 
